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iAbstract
Regardless of the considerable efforts, there have been no major breakthroughs in the
development of effective oral protein/peptide delivery. When compared to parenteral
administration, oral delivery can significantly improve the patients’ quality of life,
especially in chronic conditions, such as diabetes mellitus (DM), which requires multiple
injections daily. However, oral absorption of proteins/peptides is severely limited by their
physico-chemical properties and various physiological barriers in the gastrointestinal tract.
Porous silicon (PSi) has emerged as a promising drug delivery system, owing to its
beneficial properties, such as top-down production, customizable particle and pore
morphology, easy surface modification, simple drug loading, biodegradability and
biocompatibility. Thus, the aim of this dissertation was to develop a multifunctional PSi
based platforms that would be able to overcome the physiological barriers and efficiently
deliver insulin and glucagon-like peptide-1 (GLP-1) orally.
First, the influence of different PSi surface chemistries was evaluated on the intestinal
transport of insulin. Due to the negatively charged surface of PSi, there was minimal
interactions with the intestinal cells. Thus, chitosan, a polycationic mucoadhesive
biopolymer with permeation enhancing effect, was used to modify the surface of the PSi
microparticles. When comparing different surface modification techniques, chemical
conjugation of chitosan to PSi exhibited strongest cellular interaction, and the highest
insulin permeation and uptake across the intestinal cell monolayers. Secondly, three
different nanoparticles (NPs) were developed based on lipids, polymers and PSi, with and
without chitosan coating, and evaluated as potential oral GLP-1 delivery system. The results
showed that the chitosan-modified PSi NPs were the most efficient nanosystem with the
best loading degree and the highest GLP-1 permeation across the cellular monolayer.
 To overcome several physiological barriers, the next step was to develop a multistage
nanocomposite comprising of chitosan-conjugated PSi NPs that were coated with a pH
responsive polymer, in order to deliver GLP-1 and dipeptidylpeptidase-4 (DPP4) inhibitor
simultaneously via the oral route. This multistage nanosystem showed enhanced GLP-1
transport across the intestinal cell monolayers and across the rat intestinal tissue.
Furthermore, the nanosystem also demonstrated hypoglycemic effect in vivo after the oral
administration in diabetic rats. The efficacy of the nanosystem could be attributed to the
combined effect of the permeation enhancing chitosan-modified PSi NPs, the presence of
DPP4 inhibitor that prevented GLP-1 degradation, and the pH responsive coating that
helped in avoiding premature GLP-1 release/degradation in the stomach.
Moreover, it was shown that the mucoadhesivity and permeation enhancing ability of
chitosan-modified PSi NPs could be significantly increased by further surface modification
of NPs with either L-cysteine or cell-penetrating peptide (CPP). It was disclosed that
electrostatic interactions between the NPs and the glycocalyx were the most prominent
pathway for the transport and uptake of insulin from the NPs, together with the contribution
of active transport, adsorptive endocytosis and clathrin-mediated endocytosis.
Overall, advanced PSi-based systems were developed which successfully overcame
several limitations associated with the oral delivery of biomacromolecules, and thus,
showed high clinical potential as oral protein/peptide delivery systems for DM therapy.
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11 Introduction
In the last decades, the popularity of proteins and peptides as therapeutic agents have greatly
increased, mainly because of their high specificity, potency and effectiveness [1]. This
popularity of therapeutic proteins and peptides is further facilitated by advancements in the
field of biotechnology and analytical techniques that have allowed large-scale production
of several proteins and peptides with high purity [2]. Currently, the market for such drugs
is growing steadily with more than 200 biopharmaceuticals approved in both the United
States and European Union [3]. However, due to the instability and insufficient
bioavailability of proteins and peptides, most of these biomacromolecules are only
administered via the parenteral route [4]. Although the parenteral administration leads to
high bioavailability, the pain and trauma caused can greatly deter the patient compliance.
Furthermore, injectable products have higher manufacturing costs due to the sterility
requirements [4, 5]. Thus, several alternative non-invasive routes have been explored for
delivering the proteins and peptides, such as pulmonary, nasal, buccal, rectal, ocular,
transdermal and oral [4, 5]. The need of non-invasive delivery systems is even more evident
for diabetes mellitus (DM), due to the chronic nature of the disease and the need of two or
more injections of insulin per day for effective glycemic control in T1DM patients [6].
Insulin and glucagon-like peptide-1 (GLP-1) are the proteins/peptides used in DM therapy.
In DM, the use of oral route can have additional benefits for insulin and GLP-1 delivery, as
it more closely mimics the endogenous physiological pathway, thus allowing better glucose
homeostasis [7-9].
Regardless of several benefits of oral delivery of proteins and peptides, the poor oral
bioavailability (usually less than 1–2%) severely limits their therapeutic outcome [5, 10].
There are several factors that act together to restrict the oral absorption, which must be
carefully considered while developing efficient oral protein and peptide delivery systems.
These factors include the physicochemical properties of proteins/peptides (e.g., molecular
weight, stability, hydrophilicity, molecular size) and the physiological barriers in the
gastrointestinal (GI) tract (e.g., variable pH conditions, enzymatic degradation,
semipermeable mucus layer and tight junctions between the intestinal epithelial cells) [5,
10, 11]. Despite the considerable amount of time and efforts invested to develop innovative
approaches which could overcome the limitations of oral protein and peptide delivery, an
effective system still remains unaccomplished [10].
There are various strategies to enhance the bioavailability of proteins and peptides after
oral administration. One of the strategies includes the modification of the protein/peptide
structure to impart hydrophobicity or to make the compound stable against the enzymatic
degradation [12]. However, such modifications could compromise the biological activity of
the proteins/peptides [12]. Another popular approach explored is the formulation approach,
such as the use of permeation enhancers, mucoadhesive compounds, and micro- and
nanosystems [13-15]. The particulate-based drug delivery systems have several benefits,
such as modifiable surface properties to acquire tailored cellular interactions, dual drug
delivery for synergistic therapeutic outcome, pH-responsivity that allows protection from
the harsh gastric conditions, as well as site specific controlled drug release [16]. A number
2of drug delivery systems have been studied for the oral delivery of proteins/peptides, such
as polymer, lipid, and porous silicon (PSi)-based micro- and nanosystems [17-20].
Among several drug delivery systems, the PSi based system has shown great potential
as a carrier for proteins and peptides [21-24]. This mesoporous carrier has several
advantageous properties, such as custom-made particle and pore morphology, simple
surface modification (physical adsorption or chemical conjugation), mild drug loading
conditions, incorporation of diverse molecules or NPs, and established biocompatibility and
biodegradability [25-27]. Nevertheless, the negatively charged surface of the PSi materials
hinders the interaction of the system with the mucus layer and the intestinal epithelia due to
the repulsion from the negatively charged mucin glycoproteins. Therefore, chitosan, a
polycationic biopolymer would be a beneficial addition to the surface of PSi-based carriers,
which would inherit mucoadhesive and permeation enhancing properties to the PSi carrier
[28, 29]. Further modification of the chitosan-modified carrier systems with thiolated
groups or cell-penetrating peptide (CPP) could further facilitate and improve the particles’
interactions with the intestinal epithelia to enhance the transport of the encapsulated
biomacromolecules. Thiolated chitosan forms disulfide bonds between the immobilized
thiol groups and cysteine-rich subdomains present in the mucus glycoproteins, thereby
greatly increasing the mucoadhesion property of the compounds [30]. Likewise, a positively
charged CPP has the ability to augment the intracellular transport without causing any
damage to the cells [31].
The harsh acidic and enzyme–rich gastric environment can lead to the degradation of
the proteins and peptides, resulting in the substantial loss of the expected therapeutic
outcome. Consequently, an enteric coating of the carrier is a crucial step to overcome the
instability issues [32]. One approach that could be utilized to form polymeric coatings on
the PSi particles is aerosol flow reactor (AFR) technique. AFR is a simple single-step
process to coat micro- and nanoparticles (NPs) with polymers, and has been previously used
to prepare different micro- and nanoparticles successfully [33-35]. The possibility to avoid
harsh organic solvents during the coating process is an added benefit for this process. This
method allows a close control of the particle properties by easy regulation of the temperature
and residence time in the heating chamber [36-38]. Moreover, the polymeric coating also
provides an additional site for incorporating another drug, thus providing a possibility for
dual-drug delivery [21].
This dissertation focuses on the development of PSi-based micro- and nanosystems for
the oral delivery of insulin and GLP-1 for DM therapy. Chitosan was employed to enhance
the mucosal and cellular interactions of the developed systems with the intestinal epithelia,
along with the enhancement of intestinal permeability of the drugs. Furthermore, thiolation
and CPP modification of the systems were performed to augment the permeation
enhancement of the encapsulated protein/peptide. The understanding on how the developed
PSi-based systems functioned was also acquired by studying the mechanisms of insulin
uptake and transport across intestinal cellular monolayer. This work also focuses on
developing multifunctional nanosystems by enteric coating, in order to deliver peptides
efficiently and successfully via the oral route.
32 Review of the literature
2.1 Diabetes mellitus (DM)
Diabetes mellitus (DM) is a group of metabolic disorders mainly characterized by the high
blood glucose levels (hyperglycemia) and disturbances in the metabolism of carbohydrates,
fats and proteins [39]. It is mainly caused due to partial or absolute loss of insulin production
and/or insulin resistance in target cells [39-41]. According to the International Diabetes
Federation, in 2014 there were 387 million individuals suffering from DM worldwide, and
this number is expected to rise to 592 million by 2035, making DM one of the biggest health
problems in the world with very high socio-economic impact [42]. In Europe alone, ca. 52
million people suffer from diabetes, out of which 33.1% remain undiagnosed [42]. The main
symptoms of DM include hyperglycemia with polyuria, polydipsia, weight loss, polyphagia,
ketoacidosis and blurred vision. In long term, DM can lead to severe complications, such as
hypertension, retinopathy, nephropathy, acute neuropathy, amputation and cardiovascular
diseases [39].
2.2 Aetiological classification of DM
2.2.1 Type 1 DM
Type 1 DM (T1DM), also known as insulin-dependent DM or juvenile-onset diabetes,
represents 5–10% of the total DM cases [41, 43]. It is characterized by absolute loss of
insulin production in the body due to the destruction of insulin producing pancreatic ? cells,
which is considered to be triggered by immune-associated, if not immune mediated
mechanisms [43]. The rate of ? cells destruction is rather variable, thereby causing
differences in the onset of disease, from as early as childhood (most common) to as late as
the ninetieth years [39, 40]. The progressive T1DM shows ketoacidosis as the first indicator,
but the slower forms can show mild hyperglycemia, which can rapidly change to a severe
state of hyperglycemia or ketoacidosis in the presence of stress or infections [39, 40].
Exogenous insulin administration is required to maintain normoglycemic levels and to
prevent the occurrence of side effects, which if uncontrolled can lead to coma and death [41,
44]. The aetiology of the disease is not clearly defined, but it is mostly related to the genetic
predisposition and environmental factors [41].
2.2.2 Type 2 DM
Type 2 DM (T2DM), also known as non-insulin dependent DM or adult onset diabetes, is
responsible for 90–95% of the DM cases [41]. In T2DM, there is a relative loss of insulin
production and/or loss of insulin action. In some cases, high blood glucose levels are
4observed with normal or elevated insulin levels and impaired insulin sensitivity. However,
in other cases, the hyperglycemia observed is related to relative loss of insulin production
with normal insulin action [39, 40]. The symptoms of T2DM are not easily noticeable
because of the presence of only mild and gradual hyperglycemia, leading to a large number
of undiagnosed cases [39, 41]. Such T2DM patients are at risk of having micro- and
macrovascular diseases. The cause of this disorder is not clearly understood. Nevertheless,
the risk of T2DM is often associated with age, obesity and sedentary lifestyle. Also, the
patients who have been previously diagnosed with gestational DM (GDM), hypertension,
dyslipidemia and genetic predisposition (complex and not clearly understood), may develop
T2DM [39]. Several pharmacological (oral hypoglycemic agents) and non-pharmacological
(e.g., weight loss, diet, and physical activity) treatment approaches are applied alone or in
combination to restore normoglycemia [45].
2.2.3 Other types of DM
GDM is another type of DM, which occurs in women during pregnancy. Such women either
can continue to have DM or can show normal glucose tolerance after the end of pregnancy.
Nonetheless, the risk of subsequently developing T2DM is high in such cases [39, 41]. There
are several other types of DM, which will not be dealt here in detail, such as (i) genetic
defects of ? cell functions, (ii) genetic defects on insulin action, (iii) exocrine pancreas
disease, (iv) endocrinopathies, (v) drug or chemical induced, (vi) infection-induced, (vii)
uncommon forms of immune-mediated diabetes, and (viii) other genetic syndromes [39,
41].
2.3 DM treatment
The Diabetes Control and Complications Trial and the United Kingdom prospective
diabetes study have reported that the glycemic control is the principal way of preventing the
occurrence of diabetic complications [46, 47]. DM requires chronic treatment to control the
blood glucose levels and prevent the occurrence of both acute and long-term life-threatening
complications associated with it. In addition, the type of pharmacotherapy also depends on
the underlying pathological condition.
2.3.1 Insulin therapy
Insulin is the most versatile and effective therapy used to control blood glucose levels in
DM patients. Replacement therapy with insulin involves its exogenous administration by
subcutaneous injections, multiple times a day [48]. For the patients diagnosed with T1DM,
hormonal replacement therapy with insulin is inevitable. These patients only require small
doses of insulin to maintain glucose homeostasis, as there is no loss of insulin sensitivity,
despite the absolute loss of insulin production. Conversely, for T2DM patients, due to the
5poor insulin sensitivity, higher doses of insulin are required with gradual dose increase [49].
Nevertheless, the occurrence of hypoglycemic events is one of the major side effects of
insulin therapy [50].
Since the discovery of insulin by Banting and Best in 1921, there has been great progress
towards the production, purification and structural modification of insulin to achieve
different pharmacokinetic profiles [51]. Insulin is a heterodimeric polypeptide divided into
two chains, A and B, linked together by three disulfide bonds as shown in Figure 1 [51]. A
human preproinsulin consists of 110 amino acid residues and comprises of A-chain (21
amino acids), B-chain (30 amino acids), C-peptide (31 amino acids) and signal peptide (24
amino acids). The preproinsulin is cleaved to obtain the mature insulin peptide, consisting
of only the A- and B-chains [51].
Figure 1 Primary structure of human insulin.
Insulin is produced by the ? cells of islets of Langerhans in pancreas and its release is
stimulated by glucose in a concentration dependent-manner [51]. Insulin release is a very
dynamic and complex process, and it occurs in biphasic pattern with a first rapid phase that
lasts only few min, followed by a sustained phase [52, 53]. Insulin acts on different tissues
(e.g., liver, adipose tissues, muscles and brain), where it influences the glucose uptake,
glycogenesis, glycogenolysis, and glycolysis. In addition, insulin is also involved in
carbohydrate, lipid and protein metabolism [51].
Insulin analogues are mainly characterized based on the onset of action, duration of
action and peak effect. The rapid acting insulin analogues have an onset of action of 15
minutes with peak at ~1 h. Insulin Glulisine (Apidra®), Insulin Lispro (Humalog®) and
Insulin Aspart (Novolog®) are the different types of rapid-acting insulin. The regular or
short-acting insulin (e.g., Humulin® R and Novolin® R) is effective for 3–6 h with its peak
at ~2–3 h. The intermediate acting insulin, Insulin NPH (e.g., Humulin® N and Novolin®
N), is effective for a period of ~12–18 h. The long acting insulin tends to lower the blood
glucose level over a 24 h period. Insulin Detemir (Levemir®) and Insulin Glargine (Lantus®)
are the two types of long-acting insulin [54, 55].
62.3.2 Incretin therapy
The treatment regimen for T2DM patients is more complex, and usually includes life style
modification and/or drugs, as the first line of treatment. The selection of the oral
hypoglycemic agents used, with or without insulin, depends on several considerations, such
as drug interactions, side effects, costs and drug efficacy [45]. The drugs used for the
treatment of T2DM are sulfonylureas (stimulate insulin secretion), biguanides (suppress
hepatic glucose secretion), ?-glucosidase inhibitors (delay digestion and intestinal
absorption of carbohydrates) or thiazolidone and metformin (improve insulin sensitivity and
peripheral glucose uptake) [56]. Despite being widely used, these treatment approaches fail
to address the continuous loss of ? cell function with time and weight gain associated with
the T2DM [56].
In the past decades, the use of incretin hormones in DM therapy has emerged as a
potential treatment approach, as evidence of the role of incretin polypeptides in post-
prandial glycemic control have been reported [57, 58]. La Barre, in 1932, first coined the
term “incretin effect”, referring to the gut hormones that stimulate insulin secretion after
nutrient ingestion [57-59]. The first incretin hormone to be discovered was the gastric
inhibitor peptide (GIP), also known as glucose-dependent insulinotropic polypeptide. It is a
42 amino acid peptide that is secreted from the K cells present on the proximal small
intestine [60]. However, it was realized later that GIP was not responsible for the full
incretin effect, revealing the presence of another incretin factor released from the distal
region of the bowel [61, 62]. Subsequently, the second incretin hormone, GLP-1, was
discovered in 1987 [63, 64]. GLP-1 is synthesized from the enteroendocrinal L cells present
in the distal ileum and colonic mucosa as a 37 amino acid peptide GLP-1 (1–37), which is
cleaved into two circulating forms of GLP-1 (7–37) and (7–36) [63, 65]. Although both the
forms have equally potent insulinotropic effect, GLP-1 (7–36) is more abundant [65]. The
primary structure of GLP-1 (7–36) is shown in Figure 2. The secretion of both incretin
hormones is stimulated by ingestion of carbohydrates and lipids containing diet [62], and
thus secreted incretin hormones act on the G-protein coupled receptors in pancreatic ? cells,
resulting in the enhancement of the release of insulin containing granules [66].
Figure 2 Primary structure of GLP-1 (7–36), indicating the position where dipeptidyl peptidase
(DPP4) enzyme cleaves the peptide to yield the inactive form of the molecule.
7In 1986, Nauck and colleagues showed that patients who suffered from T2DM had
deficient incretin effect [67]. The deficient incretin effect was due to the defective GIP
action and reduced GLP-1 secretion, thus, establishing only GLP-1 as a potential clinical
target for T2DM therapy [67-69]. One of the main advantages of GLP-1 as an antidiabetic
agent is that its effect is lost when the blood glucose concentration is lower than 77 mg/dL,
thereby reducing the risk of unwanted hypoglycemic events [70, 71]. Moreover, GLP-1 also
has several other actions, such as (i) up-regulation of insulin biosynthesis, (ii) enhanced
insulin gene expression, (iii) increased ? cell mass, (iv) inhibition of glucagon secretion,
and (v) delaying of gastric emptying and suppression of food intake (as shown Figure 3)
[59, 62]. All of these favorable actions establish GLP-1 a highly promising antidiabetic
agent. GLP-1 also affects other peripheral tissues, such as brain, heart and liver, as shown
in Figure 3 [59, 72]. However, the bioactive GLP-1 needs to be administered by continuous
infusion as the peptide has a very short half-life of 2 min, owing to rapid degradation by the
proteolytic enzyme, dipeptidyl peptidase-4 (DPP4) [73, 74].
Figure 3 The action of GLP-1 on several peripheral tissues. GLP-1 acts directly on endocrine
pancreas, heart, stomach and brain, and indirectly on liver and muscle [72].
DPP4, a CD26 serine protease, deactivates peptides and proteins by cleaving them at the
amine terminal which has alanine or proline amino acids in position 2, as shown in the
structure in Figure 2 [75]. The DPP4 enzyme is abundantly available in both membrane-
bound forms (liver, kidney, lungs, intestine, pancreas, spleen, adrenal gland, and the central
nervous system) and as soluble protein in the circulation [59, 73]. Since, DPP4 enzyme
degrades and inactivates GLP-1, it has also been established as a potential clinical target
8[76]. Studies have shown that, in human subjects with T2DM, when the DPP4 activity was
inhibited for 4–52 weeks, potentiation of ? cell function, enhanced insulin sensitivity and
suppression of plasma glucagon were observed, which could be beneficial for the treatment
of T2DM [77-79]. In addition, selective DPP4 inhibitors have shown to be comparatively
safe in high doses in mice, rats, and dogs [80].
There are several DPP4 inhibitors, such as vildagliptin (Novartis) and sitagliptin
(Merck), which efficiently inactivates the DPP4 enzyme and, consequently, increases the
GLP-1 levels. A potent and selective DPP4 inhibitor, NVP-DPP728, which potentiates
insulin release in response to glucose-containing meals, has also been reported [81]. The
inhibitor is described to have an excellent oral bioavailability and potent antihyperglycemic
effect [82]. The long-term inhibition of DPP4 enzyme with NVP-DPP728 showed
improvement in the glucose tolerance in both normal and glucose-intolerant mice through
improved islet function, increased insulin secretion, and protection from increased islet size
in insulin resistance, as well as with improved prandial glucose homeostasis [83, 84].
2.4 Oral protein and peptide delivery for DM therapy
Oral protein and peptide delivery as a non-invasive alternative approach is still one of the
biggest challenges for formulation scientists, with oral insulin delivery being the holy grail
of DM treatment. The delivery of such biomacromolecules as an injectable formulation has
several drawbacks associated with it, such as the poor patient compliance caused by the fear,
pain and physiological trauma associated with injections [2]. In DM therapy in particular,
despite the satisfactory performance of the current parenteral insulin therapies, there are
numerous adverse effects associated with it, such as hypoglycemic episodes, infections at
the injection sites, peripheral hyperinsulinemia, local hypertrophy due to the insulin
deposition at the site of injection, insulin edema, and atherosclerosis due to the irregular
insulin absorption [7]. The need of life-long insulin therapy with more than 60,000
injections throughout the patients’ lifetime is a major limitation [40, 85]. In addition, the
cost-ineffectiveness, need for proper storage conditions, and high risk associated with the
use of parenteral route are other limiting factors for this administration route [86].
Consequently, a number of alternative non-invasive delivery routes for proteins and
peptides have been studied, such as oral, pulmonary, buccal, nasal, ocular, transdermal and
rectal [26]. Among them, the oral route is the most popular one because of its accessibility
and close resemblance to the physiological pathways of both insulin and GLP-1 [7-10].
Furthermore, the extensively used subcutaneous administration of insulin leads to direct
entry in the peripheral circulation, exposing the peripheral tissues to abnormally high
amounts of insulin, thereby causing peripheral hyperinsulinemia [7, 87]. Additionally, in
contrast to the parenteral route, the oral route also has other advantages, such as high patient
compliance, ease of administration and relatively low production cost [10, 88].
A number of pharmaceutical companies have also invested in developing a viable oral
delivery system for DM therapy, with some of them already in clinical stages. Table 1
summarizes some of the efforts made by industry on developing oral formulations for
insulin and GLP-1, and their current development status.
9Table 1 Examples of oral protein and peptide delivery systems for DM therapy under clinical
trials.
Product Technology Description Status Reference
CapsulinTM OAD and
IR (Diabetology, UK)
Axcess™ delivery technology enteric-coated
capsule containing a mixture of insulin, an
absorption enhancer, and a solubilizer.
Entering Phase IIb
(OAD) and Phase
II (IR)
[89]
ORMD-0801
(Oramed, Israel)
A mixture of insulin and adjuvant that
protects and promotes intestinal uptake of
insulin, filled in an enteric-coated capsule.
Phase II [90]
I320GT (NN1957)
(Novo Nordisk,
Denmark)
A long-acting oral basal insulin analogue as
once-daily tablet treatment. Phase I [91]
Oral HDV Insulin
(Diasome, USA)
Hepatic directed liposomal vesicles for oral
insulin administration.
Approved for
Phase III [92]
OG987SC (NN9927)
(Novo Nordisk,
Denmark)
A once-daily tablet treatment of a long-
acting oral GLP-1 analogue. Phase I [91]
ORMD-0901
(Oramed, Israel)
Oral GLP-1 capsule based on the company’s
POD™ technology. Phase I [90]
2.5 Barriers to oral protein and peptide delivery
The natural course of ingested proteins and peptides present in our diet involves breakdown
into small peptide fragments and/or component amino acids, which are then easily absorbed
via the intestinal epithelium. However, following the same route, the therapeutic proteins
and peptides, like insulin and GLP-1, will completely lose their physiological action after
the breakdown. In addition, the absorption of the remaining small fraction of active
proteins/peptides is further diminished by their poor permeability across the mucus covered
tightly arranged intestinal epithelium [10]. Hence, it is of utmost importance to understand
the features and functions of these physical and biochemical barriers of the GI tract to
develop an effective oral protein/peptide delivery system.
2.5.1 The physical barrier
The GI epithelium layered with mucus acts as physical barrier for the absorption of proteins
and peptides, permitting only selective absorption of nutrients, fluids and electrolytes, whilst
avoiding the passage of harmful substances and pathogens [10, 93]. The length of the GI
tract is ~6 m, and has high regional variations in regards to pH, mucosal thickness and
composition, residence time, enzymatic activity and surface area [32].
The small surface area, harsh acidic environment along with the presence of the pepsin
enzyme renders the stomach as an unfeasible site for protein/peptide absorption [10]. In
contrast, the human intestinal epithelium is a highly absorptive region with a total surface
area of 300–400 m2. The cells comprising the small intestinal epithelium are categorized
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into absorptive enterocytes, secretive goblet, enteroendocrinal and Paneth cells, and M cells
(in Peyer’s patches), as shown in Figure 4 [5, 94]. The enterocytes are the most abundant
and rapidly renewing epithelial cell lines (life span of 3–4 days) which are derived from the
stem cells present at the base of the intestinal crypts [5]. These cells are compactly packed
with organized and well-ordered microvilli present on the apical side. The presence of
microvilli results in expanded surface area, allowing enhanced nutrient absorption [10].
Figure 4 Schematic representation of the structure of the intestinal epithelium composed of
mucus layer, enterocytes, goblet cells, Paneth cells, and M cells in Peyer’s patches.
Goblet cells are the second most abundant cell type in the intestinal epithelium and they
are located interspersed between the epithelial cells. These cells also have a lifespan of 3–6
days, and their number increases from the duodenum to the terminal ileum [5, 95]. The third
type of cells present in the intestinal epithelium are the Paneth cells which are located at the
base of crypts of Lieberkühn and they have the ability to kill bacteria by secreting anti-
microbial proteins [95]. Additionally, specialized epithelial cells, named M cells, are present
in specialized regions in the intestinal epithelium known as Peyer’s patches. These are
flattened cells with no mucus layer present on their surfaces [5, 96]. Furthermore, low
aminopeptidase activity in the region of Peyer’s patches and high endocytic activity of these
cells provide a good site for protein/peptide absorption [5, 97]. The intestinal epithelium
also consists of hormone secreting enteroendocrinal cells [5, 95]. Besides the small
intestine, the colon also acts as a possible absorption site for proteins/peptides, mainly due
to the absence of enzymatic activity and prolonged residence time [98].
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The physical integrity of the intestinal epithelium can be attributed to the presence of
tight junctions (TJs) or Zonula Occludens (ZO) in the paracellular space between adjacent
epithelial cells [5, 11]. Owing to the presence of TJs, the intestinal epithelium acts as the
rate-limiting barrier for paracellular transport, regulating the passage of various components
between the intestinal lumen and submucosa. TJs are dynamic structures mainly composed
of transmembrane integral proteins (Claudins (CLDNs), occludens and junctional adhesion
molecules), intracellular plaque proteins (ZO-1, ZO-2, ZO-3, cingulin, and 7H6) and
regulatory proteins [11, 99]. The complex and organized interplay between these
components are very important for the assembly of the TJs. The transmembrane proteins
are responsible for sealing the adjacent cells, and the intracellular plaque proteins play an
important role in giving structural support to the TJs [11, 100]. The regulatory proteins are
assumed to be involved in signal transduction and cell adhesion, however, their involvement
in the regulation of TJs has not been clearly defined yet [11, 101]. Furthermore, the
architecture of actin cytoskeleton has been shown to be vital for the function of TJs, as
several actin binding proteins can serve as an anchor to the plasma membrane [101].
2.5.2 The mucosal barrier
The mucus layer covering the intestinal epithelium is one of the limiting factors for the
absorption of orally delivered drugs [102]. The mucus barrier functions as a protective
barrier for the epithelial cells against the harsh environment, and helps in trapping and
clearing pathogens and foreign particles [103, 104]. The barrier is composed of three
different layers. The first layer is the membrane-bound mucin, known as glycocalyx, on the
top of the epithelial cells. It plays a role in docking the mucus layer to the epithelium and
may have a role in mucoadhesion [104, 105]. The mucus produced by the goblet cells
blanketing the glycocalyx acts as the second barrier. The last barrier is composed of
bicarbonate ions secreted by the epithelial cells [102].
Mucus is a highly hydrated (?95 % water content) viscoelastic gel lubricating and
protecting the different surfaces of the body [103, 106]. It is a complex heterogeneous blend
of carbohydrates, proteins, lipids, lysozymes, antibodies, cell debris, bacteria and inorganic
salts [105, 107]. Among them, the major components are the large mucin fibers that are
entangled and crosslinked with each other by disulfide linkages and hydrophobic
interactions, and are mainly secreted by the goblet cells and submucosal glands. The mucin
fibers are rich in negatively- charged glycosylated regions and hydrophobic domains [108].
The mucin fibers forms a dense porous structure due to the high degree of crosslinking,
which creates steric obstruction [109].
The thickness of the mucus layer across the GI tract varies extensively, with the thickest
mucus layer present in the stomach and colon, and the thinnest in the jejunum [93]. There
is a continuous turnover of mucus, (intestinal turnover of 50–270 min), where the old layer
is shed off and discarded, digested or recycled [109, 110]. The mucus layer offers the first
line of defense against several foreign materials that enter the intestine and is an important
barrier against the absorption of protein and peptide absorption. Thus, the underlying
characteristics of this layer must be clearly understood to overcome it.
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2.5.3 The biochemical barrier
Besides the physical barrier, the GI tract also presents a biochemical barrier for oral protein
and peptide delivery. This biochemical barrier comprises of the high pH variations spanning
the GI tract and the presence of several enzymes, such as pepsin, trypsin, chymotrypsin,
aminopeptidase and carboxypeptidase [102, 111]. The site of enzymatic degradation can be
the lumen, brush border, cytosol of enterocytes, lysosomes or other cell organelles [112].
The highly acidic environment in the stomach (pH 1.5–3.5) and the presence of proteolytic
enzyme, pepsin, induces hydrolytic degradation of the ingested proteins and peptides [102,
112]. Moreover, duodenum and jejunum have high brush border enzymatic activity, which
together with other digestive enzymes create harsh conditions for the proteins and peptides
[102]. Nonetheless, the Peyer’s patches present in the duodenum and ileum have ~20–30 %
of the aminopeptidase activity as compared to the nearby regions [97]. In addition to the
enzymatic degradation, as the pH rises to ~6 when entering the small intestine, there is a
possibility for some of the proteins and peptides to be precipitated, which cannot be easily
re-dissolved [102].
2.6 Intestinal drug transport mechanisms
The transport of drugs across the intestinal epithelium can be either active (energy
dependent) or passive (non-energy dependent) [113]. Active process involves the transport
against the concentration gradient, and requires direct or indirect consumption of adenosine
tyrosine phosphatase (ATP) molecules [113]. Passive transport involves the movement of
molecules in the direction of a concentration gradient, following the Fick’s law of diffusion
[10]. The mechanism through which a molecule is transported depends on its
physicochemical characteristics, such as molecular weight, chemical structure, pKa and
hydrophilic–lipophilic balance [114]. There are two possible drug transport pathways across
the intestinal epithelium: paracellular and transcellular (receptor-mediated and carrier-
mediated), as depicted in Figure 5.
Figure 5 Schematic representation of different transport mechanisms in the intestine: 1.
Paracellular pathway; 2. Active transport; 3. Electrostatic interactions between
positively charged NPs and negatively charged glycocalyx 4. Adsorptive mediated
endocytosis 5. Clathrin-mediated endocytosis; and 6. Caveolae-mediated endocytosis.
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The paracellular transport involves the passage of molecules through the water-filled
intercellular space between two conjoining epithelial cells [10, 102, 114]. In the case of
hydrophilic proteins/peptides, the paracellular route is the most preferred transport route,
and is determined by their molecular size and ionic charge [115]. However, the convoluted
pathway and the presence of TJs (as aforementioned) between the epithelial cells can greatly
reduce the possibility of easy passage of molecules [115]. The paracellular space is in the
order of 15 Å, which greatly limits the passage of large molecules through this pathway
[116]. Nonetheless, it has also been reported that high conformational flexibility of proteins
and peptides makes it possible for larger molecules to use this route as well [117]. Since the
paracellular space comprises of only 0.01–0.1% of the total intestinal surface area, the
amount of drugs transported via this route is limited, thus suggesting the involvement of
other routes complementing the paracellular passage [10, 113].
Transcellular drug transport involves the movement from the apical to the basolateral
membranes of the epithelial cells [10]. As the cell membranes are composed of lipid
bilayers, passive transcellular transport is highly favorable mostly for lipophilic drugs. The
active transcellular route involves endocytosis of the molecule, starting at the apical
membrane, transport through the cells and release at the basolateral side [118]. Transcellular
passage occurs mainly in M cells and the enterocytes. Studies have shown that an intestinal
model comprising of M cells had 5-fold higher transport when compared to Caco-2 cell
monolayers [119, 120]. Phagocytosis via M cells, micropinocytosis, clathrin-mediated
endocytosis, and caveolae-mediated endocytosis are examples of active transcellular
mechanisms [121]. Clathrin-mediated endocytosis, which is able to internalize particles up
to 15 nm in size, and phagocytosis, which can engulf micron-sized particles, are receptor-
mediated endocytosis mechanisms. Such receptor-mediated mechanisms involve the
binding of the ligand to the receptor present on cell’s surface and then internalization
through coated vesicles [102, 122]. The fate of such mechanism of cellular internalization
are highly dependent on the ligand-receptor binding [114, 122].
2.7 Strategies for enhancing the oral absorption of proteins and
peptides
There are several approaches that have been studied in order to enhance the oral
bioavailability of biomacromolecules and can be broadly classified into two categories:
chemical structural modification and formulation based strategies [114]. The structural
modification approach involves altering the physicochemical properties of the
protein/peptide by modifying its molecular structure, whilst maintaining or enhancing its
pharmacological action. The commonly used chemical strategies include prodrug
formation, PEGylation, lipidization, site-specific mutagenesis and glycosylation [114, 123].
Nonetheless, these optimization methods are limited by the structural complexity, possible
inefficient modifications and additional production costs for the structural modifications
[123, 124]. Alternatively, the formulation approach exploits the use of different
pharmaceutical excipients and novel drug delivery systems to successfully deliver
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proteins/peptides orally, by protecting them against the enzymatic degradation and/or by
enhancing the intestinal permeability [10, 114].
The following sub-sections shed some light on the different formulation approaches
investigated to deliver proteins/peptides.
2.7.1 Absorption enhancers
Absorption enhancers are used to enhance the intestinal permeability of proteins and
peptides, via the paracellular or transcellular route [114, 123]. Bile salts [125], chitosan [28],
thiomers [126], cell-penetrating peptide (CPP) [17], medium chain fatty acids [127],
chelators [128], and ZO toxins [129] are some examples of the commonly used of absorption
enhancers [2, 114, 115, 130]. All these absorption-enhancing agents interact with different
components of the intestinal epithelium to increase the transport of drugs. The absorption
enhancing mechanisms may include changing of the membrane fluidity, decreasing the
mucus viscosity, opening up of TJs, and cell penetration enhancement [2]. However, once
the integrity of the intestinal epithelium is compromised either by altering the permeability
of the cell membrane or by opening up of the TJs, there is a high possibility for undesired
entities (such as pathogens, bacteria and foreign particles) to also enter the systemic
circulation, leading to severe complications [131]. Thus, local irritation and long-term
toxicity must be considered while using these absorption enhancers. Nonetheless, several
absorption enhancers with reversible influence on the intestinal epithelium have also been
reported [132].
2.7.2 Enzyme inhibitors
Proteins and peptides are highly susceptible to degradation by several enzymes present in
the GI tract. Therefore, inhibiting the degrading enzymes, such as trypsin, chymotrypsin,
carboxypeptidases and aminopeptidases, can be one of the approaches to increase the
amount of biologically active molecules [10, 114]. The selection of enzyme inhibitors is
dependent upon the nature of the protein and the enzymes involved in its metabolism. Long
term use or the use of non-specific inhibitors can lead to unwanted toxic effects, and can
possibly alter the metabolism of other proteins in our normal diet [15, 114]. There have also
been efforts to inhibit the enzymatic action without the use of any inhibitors, by altering the
physiological conditions, such as the pH [133].
A number of inhibitors have been studied for enhancing the permeability of insulin, such
as aprotinin, bacitracin, soybean trypsin inhibitors, and Bowman–Birk inhibitor [134, 135].
In the case of GLP-1, DPP4 inhibitors are the most commonly used inhibitors to prolong its
very short half-life [65].
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2.7.3 Increasing the GI retention time
Another important strategy that can be employed for improving the transport of proteins and
peptides is increasing their residence time in the GI tract, which can be achieved by
mucoadhesion (specific or non-specific) [136]. Besides increasing the residence time, the
mucoadhesive systems also allow the biomacromolecules to come in close proximity to the
absorption site in the intestine [136]. Chitosan, thiomers, methacrylate, and alginate are
some of the most commonly used mucoadhesive agents [137, 138]. Khutoryanskiy
categorized these mucoadhesive polymers as anionic, cationic, non-ionic, amphoteric,
thiomers, dendrimers, synthetic glycopolymers, etc. [139]. The mechanism of
mucoadhesion depends on the features of the polymers used, such as surface charge, chain
flexibility, surface tension, hydrophobicity and hydrophilicity [136]. Additionally, for
delivery systems composed of such mucoadhesive polymers, the interaction with mucus
depends on the different characteristics of the delivery system, such as size, surface area,
surface chemistry, and surface charge [105].
There are several theories that have been proposed to explain and understand the
mechanisms of mucoadhesion, and they are summarized as follows [139, 140]:
 Electronic theory proposes the involvement of electrostatic interactions between the
negatively charged mucin with the oppositely charged materials.
 Adsorption theory proposes the involvement of hydrogen bonding, van der Waals
force, hydrophobic interactions and chemisorption in mucoadhesion.
 Wetting theory correlates the surface tension to the mucoadhesion as the ability of
the mucoadhesive material, in liquid form, to spread over the mucus layer.
 Diffusion theory considers the interpenetration of the mucoadhesive material into the
mucus gel, and the diffusion of soluble mucin into the dosage form. This process is
driven by the concentration gradient.
 Fracture theory considers the difficulty to detach two previously joined surfaces.
 Mechanical theory proposes the role of roughness of the surface, which promotes
the mucoadhesion due to the increased contact surface area.
Since the process of mucoadhesion is complex in nature, more than one theory needs to
be used to explain the given conditions [140].
The adhesion process has two major stages: contact and consolidation. The contact stage
is the first step where the mucoadhesive material must come in close contact with the mucus
layer. However, the process is complicated for orally delivered systems as it is not possible
to directly place the mucoadhesive system close to the mucus layer in the GI tract [140].
Next, the consolidation stage leads to prolonged adhesion due to various physicochemical
interactions to strengthen the adhesion. Peppas and Sahlin proposed a theory explaining the
process of consolidation, which is based on the diffusion theory, and includes the
interpenetration of the mucoadhesive molecules with the mucus glycoproteins and
formation of secondary bonds. Thus, indicating the contribution of both surface and
diffusional phenomena to form strong interactions between the mucoadhesive polymer and
mucus [141].
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2.7.4 Targeting at the site of absorption
Due to the large variations along the GI tract, site specific release of proteins/peptides in
regions with a thin mucosal layer, maximum uptake and low enzyme activity, can be utilized
to obtain enhanced drug absorption [10, 142]. Additionally, the delivery of
biomacromolecules can be targeted to release in a specific region of the intestine, small or
large, by using pH-sensitive polymers [15]. Another approach can be the use of targeting
moieties for site-specific delivery of proteins and peptides [102]. Several targeting moieties,
such as lectins, vitamin B12 and peptide ligands (CSKSSDYQ) have been reported to
enhance the intestinal absorption of proteins and peptides [2, 102]. In addition, CPPs have
also been successfully applied to enhance the intestinal permeability by entering into the
cells via endocytic pathway [143]. Some promising results regarding the use of targeted oral
protein/peptide delivery have been reported, nonetheless, the possibility of toxic reactions
on the chronic use of such targeting ligands need to be further studied in detail.
2.7.5 Particulate-based carrier systems
Particulate-based delivery systems provide an alternative way to deliver proteins/peptides
orally. The incorporation of biomacromolecules into the particulate system can offer several
advantages, such as protection against the enzymatic degradation and harsh acidic
conditions in the stomach, controlled drug release, targeted delivery at the site of absorption
and enhanced intestinal absorption [2, 12]. There are different kinds of particulate systems
that have been presented as excellent carriers for oral delivery of proteins and peptides.
These particulate-based systems could be matrix-based or porous in nature, micro- or nano-
sized, composed of polymers, lipids or mesoporous materials, prepared by bottom-up or
top-down approaches. Polymeric drug delivery systems (e.g., hydrogels, micro- and
nanospheres and NPs), lipid-based drug delivery systems (e.g., micro and nano-emulsions,
liposomes and lipid NPs) and mesoporous particles (e.g., silica and silicon-based micro- and
nanoparticles) are some examples of the most investigated particulate systems for oral drug
delivery [16, 144]. The properties of the particulate carriers, such as size, surface charge,
surface chemistry and the presence of targeting ligands, have a great influence on its fate in
the GI tract [145]. For example, the uptake of the particulate system highly depends on their
size, as the intestinal uptake increases as the size of the system decreases [145, 146].
The ability to incorporate one or more strategies, such as absorption enhancement,
enzyme inhibition, mucoadhesivity, targeting and enteric coating into one optimum system
is one of the main benefits associated with the particulate systems. In addition, the
biocompatibility and biodegradability of the delivery systems are also vital for the delivery
of proteins/peptides, especially in the case of DM due to the chronic nature of the disease.
2.8 Porous silicon (PSi)
Porous silicon (PSi) was first reported 60 years ago by Uhlir at Bell laboratories [147], while
it was not until 15 years after its first reference that the porous nature of the material was
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recognized by Watanabe et al. [148]. Prof. Leigh Canham demonstrated the bioactive
property of PSi and its ability to impart either bioinert, bioactive or biodegradable nature
just by altering the porosity and pore size of the material [149-151]. These findings have led
to immense popularity of this material in biomedical applications, both in drug delivery and
biosensing [25, 150, 152, 153].
PSi materials have several advantageous properties, such as high surface-to-volume
ratio, large surface area and pore volume, high stability (e.g., thermal, chemical and
mechanical), biocompatibility and biodegradability [25]. The top-down fabrication process
allows easy scaling-up, and the pore and particle size can be easily controlled by altering
the fabrication parameters [153-155]. Furthermore, easy surface modification of PSi with
different types of biopolymers and targeting moieties also has benefit for biomedical
applications [156-158].
2.8.1 Fabrication and surface modification of PSi
The most common PSi fabrication method is electrochemical anodization, using
monocrystalline silicon (Si) wafers as a positive anode and platinum (Pt) as a negative
cathode [25, 151, 155, 159]. Aqueous or ethanolic hydrofluoric acid (HF) is used as an
electrolyte solution. The use of ethanolic solution allows reduction in hydrogen bubble
formation and enhances the electrolyte penetration into the pores, to allow uniform PSi layer
formation [25]. A schematic representation of an anodization cell used to prepare PSi is
shown in Figure 6 [25].
Figure 6 Schematic illustration of the anodization cell for one side etching of Si-wafer (A) and
construction of the cells with different components (B).
In this arrangement, the Si-wafer is placed in between two electrolyte cells with Pt
electrodes on both sides. The front side of the Si-wafer acts as the anode, and the backside
of Si, which is in close contact with conductive metal anode, serves as the cathode. When
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an etching current is applied between the electrodes, a layer of PSi is formed on the Si
surface. The metal deposition in one side of Si allows a homogenous PSi layer formation in
the front side [25, 160]. The pore morphology of PSi material can be controlled by altering
some of the fabrication parameters, such as HF concentration, electrolyte composition,
current density, wafer type and resistivity, crystallographic orientation, temperature and
illumination intensity [151, 155, 159]. Some of the other methods used for the PSi
fabrication include stain-etching and zero-current etching [161, 162].
The freshly prepared PSi is an unstable hydrogen-terminated form (Si-Hx), which is
susceptible to rapid oxidation leading to the loss of its structural and optical properties [25,
159]. Relative humidity, temperature and composition of air have great influence on the rate
and extent of oxidation [25, 159]. In drug delivery applications, the use of the native Si-
hydride form can lead to the degradation of adsorbed drugs, thereby greatly compromising
its applicability [151, 163]. Thus, as most of the applications require stable surface
chemistry, the surface of PSi needs to be stabilized prior to use.
The most common methods for stabilization of PSi are oxidation, hydrosilylation,
thermal carbonization and thermal hydrocarbonization [25]. Controlled oxidation of the
surface of PSi, to form Si–O bonds, imparts hydrophilicity to the PSi, which facilitates the
wettability and dissolution in physiological fluids [155, 164]. Thermal, anodic, photo, and
chemical methods can be used for the oxidation of the PSi surfaces. Another surface
stabilization method is hydrosilylation to yield Si-C surface with high hydrolytic stability
[151]. It involves the reaction of alkene or alkyne with Si–H bond, by thermal,
photochemical or Lewis-acid catalyzed [25, 155]. Thermal hydrocarbonization of Si is
another stabilization method, that is prepared by treating the Si–H surface with acetylene at
high temperature (500 °C) to form a highly stable hydrophobic Si–CxHy surface [165].
Further thermal treatment of Si–CxHy with undecylenic acid allows the addition of –COOH
terminated groups to the surface of the PSi layer [22, 166]. The presence of this –COOH
layer allows easy covalent attachment with other biopolymers, macromolecules, or
fluorescent dyes.
2.8.2 Drug delivery applications of PSi-based particulate systems
The understanding of the biocompatibility and biodegradability of any material is highly
important before its application in the field of biomedicine. In the case of PSi, the
relationship between bioactivity of the material and its pore morphology has already been
established [150]. In addition, it has also been shown that PSi degrades mostly into
monomeric silicic acid, which is the most naturally occurring available form of Si in the
environment [25]. A number of in vitro and in vivo studies have been performed to show
the biocompatibility of PSi, along with the evaluation of their inflammatory and immune
responses [167-172]. Shahbazi et al. showed that the toxicity of NPs was predominantly
dependent on the surface chemistry and charge of the NPs [171]. Several other studies have
also demonstrated the biocompatibility of PSi-based micro- and nanoparticles with GI cell
lines [18, 173], heart tissues [172], and human ocular cells [174].
Along with excellent biocompatibility, the unique high surface area-to-volume ratio of
the PSi system also makes it a potential candidate for drug delivery applications. In addition,
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PSi also possesses unique capability to efficiently load and control the release of drug
molecules [26, 151, 153, 175]. The drug loading and release patterns can be controlled by
altering the characteristics of PSi materials, such as surface charge, pore size, surface
hydrophilicity/hydrophobicity and loading method. Additionally, it is also influenced by the
physicochemical properties of the loaded drug [26, 155, 164]. The incorporation of drugs
into the pores of PSi can be performed by either immersion, oxidation-induced trapping,
impregnation or covalent attachment methods [155]. Out of these loading techniques, the
immersion technique is the most commonly used, as it is a simple process and has the
possibility to be performed at room temperature. This technique follows the principle of
physical adsorption of the drug molecule onto the pore surfaces of PSi. Charge and
hydrophobicity, along with the concentration of the drug loading solution, loading time and
temperature, are factors that influence the drug adsorption onto PSi [25, 152]. Depending
on the physicochemical characteristics of the drug and PSi, different drug release behaviors,
from burst to sustained release, can be obtained [157, 175].
PSi particles have been reported to enhance the solubility of very poorly water-soluble
drugs [176, 177]. This advantageous property is mainly due to the ability of PSi to confine
the drug molecules in its pores in an amorphous-like or nanocrystalline form, which has
significantly higher solubility as compared to the crystalline form [154, 178]. Sorafenib
[179], celecoxib [180], methotrexate [156, 181], ibuprofen [175], indomethacin [21],
itraconazole [182], ethionamide [183], griseofulvin [154, 175] and furosemide [175] are
some of the poorly water-soluble drugs, whose dissolution has been greatly enhanced by
incorporation in PSi particles.
In addition to the enhanced dissolution profiles of drugs, PSi has been further modified
and developed to form advanced multifunctional drug delivery systems. For example,
Herranz-Blanco et al. developed a hybrid nanocomposite made-up of PSi NPs and stimuli
responsive polymeric material, polyethylene glycol-block-poly(L-histidine), using a flow-
focusing microfluidic chip [184]. The nanocomposites were able to demonstrate plasma
stability, high cytocompatibility, reduced internalization by phagocytic macrophages and
cell growth inhibition in a pH-dependent manner [184]. Similarly, Kong et al. showed the
fabrication of an advanced biocompatible multifunctional nano-in-micro platform
consisting of PSi NPs and giant liposomes, which were also assembled in a microfluidic
chip [185]. The system was aimed at controlled co-delivery of hydrophilic and hydrophobic
drugs along with DNA nanostructures. Additionally, short gold nanorods, and magnetic NPs
were also incorporated into the system to allow photothermal and magnetic responsiveness.
The possibility of surface modification of PSi is very useful for its application as a drug
delivery system. For example, Sarparanta et al. used a gastro-retentive class II hydrophobin
protein to modify the surface of PSi NPs, with the aim to increase the gastric mucoadhesion
of the NPs [186]. The results showed enhanced biocompatibility and increased transit time
of PSi NPs in the stomach, however the mucoadhesive property was lost in the intestine
leading to rapid transit of the NPs [186]. In another example, the surface of PSi NPs were
decorated with a cell surface binding peptide to target the murine B-lymphoma cells. The
targeting moiety used in combination with PSi NPs showed efficient in vivo targeting [187].
Similarly, Wang et al. employed a simple copper-free click chemistry to modify PSi NPs
with targeting peptides, which resulted in enhanced intracellular uptake and tumor specific
targeting [157].
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PSi particles have also been successfully reported as gene delivery systems for cancer
therapy [188, 189]. Additionally, other smaller NPs, such as quantum dots [190], carbon
nanotubes [191], hollow gold nanoshells [192], and Fe3O4 NPs [193], have also been
successfully loaded into the pores of PSi. The incorporation of such NPs into the pores of
PSi have added benefits to the delivery system, such as photothermal therapy in the case of
hollow gold nanoshells [192], or targeting by magnetic field in the case of Fe3O4 NPs [193].
2.8.2 PSi for protein and peptide delivery
Developing an effective formulation for protein and peptide delivery is a complex process
and requires consideration of several factors. PSi, as a carrier for proteins and peptides,
offers a unique advantage of mild aqueous drug loading conditions and the possibility to
avoid the use of harsh organic solvents [155]. Foraker et al. reported one of the first account
of using PSi particles to encapsulate protein molecules [194]. The study presented the ability
of PSi microparticles to enhance the intestinal permeability of insulin across Caco-2 cell
monolayers. Since then, there has been several studies demonstrating the successful
incorporation of proteins and peptides into the PSi particles, aiming at drug delivery through
various routes, such as oral [21, 194, 195] and subcutaneous [22, 196-198]. Electrostatic
and hydrophobic interactions are considered the key forces that act during the
protein/peptide adsorption to the PSi pores [199, 200].
Several studies have been performed to understand different possible parameters that
can influence the adsorption of proteins and peptides into the pores of PSi particles [21, 197,
198, 201]. These factors include the nature of the protein/peptide, pore size, particle size,
surface chemistry of PSi, and loading conditions. The relationship between the size of the
protein molecule and the pore size plays an important role in determining the loading
capacity. Karlsson et al. studied the influence of the mean pore size and the thickness of the
PSi layer on the loading of human serum albumin [202]. The results showed that the albumin
was encapsulated only when the pore radius was larger than 5.5 nm. In addition, it was also
shown that when the PSi thickness layer was greater than 1 μm, albumin was not able to
occupy the available surface area completely [202]. In another study, Prestidge et al. studied
the effect of size and hydrophobicity of protein/peptide on loading efficiency in PSi wafers
[203]. In this study, two different macromolecules, gramicidin A (~1.8 kDa, hydrophilic)
and papain (~23 kDa, hydrophobic) were used. The study showed that the large hydrophobic
papain molecule was not efficiently loaded and was instead accumulated on the surface of
PSi. However, the smaller hydrophilic peptide, gramicidin A, was readily loaded into the
pores of PSi [203]. Similarly, another recent study by Pastor et al. showed that the release
of proteins could be sustained by decreasing the pore size [204]. In the study, PSi of pore
sizes > 10 nm showed 100% release in the first 2 days; however, when the pore size of PSi
was reduced to < 6 nm, sustained release for up to two weeks was achieved.
In addition to the physicochemical properties of the proteins and peptides and the pore
size of PSi, another important factor to be considered is the surface chemistry of PSi.
Kovalainen et al. investigated the influence of the surface chemistry of PSi microparticles
on the release of the peptide YY3-36 (PYY) [22]. Three different surface chemistries were
studied, namely, (i) thermally oxidized PSi (TOPSi), (ii) thermally hydrocarbonized PSi
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(THCPSi), and (iii) undecylenic acid treated THCPSi (UnTHCPSi). TOPSi presented a
hydrophilic surface and THCPSi presented a hydrophobic surface, whereas UnTHCPSi
resulted in a slightly more hydrophilic surface than THCPSi. The order of PYY release
observed was TOPSi > THCPSi > UnTHCPSi. The rapid release from TOPSi was attributed
to the hydrophilic nature of TOPSi, which allowed easy wettability and desorption of the
peptide from the surface of the particles. However, in the case of THCPSi and UnTHCPSi,
hydrophobic interactions between the peptide and pore surface, along with poor wettability,
were possibly responsible for the delayed PYY release behavior. Moreover, the possible
interaction of the carboxylic groups in UnTHCPSi with the amine groups of the peptide
further sustained the PYY release [22]. Similarly, Jarvis et al. have also shown that by
reducing the hydrophobicity of the surface of PSi by thermal oxidation, the hydrophobic
interactions between the adsorbed protein and the PSi surface are lowered and the drug
adsorption is mainly based on electrostatic interactions [200]. Thus, the aforementioned
findings indicate that the surface chemistry of the PSi can be altered to achieve optimal
loading and release profile for a given protein/peptide.
The composition and pH of the loading medium also have an influence on the loading
of proteins and peptides. For example, the loading degree of human serum albumin was
increased by up to 30% when the protein concentration was increased from 0.001 to 10
mg/mL [202]. Another important factor is the pH of the solution and the isoelectric point
(pI) of the loading protein/peptide. When the pH of the loading medium is altered, the charge
of the protein/peptide is also changed, which can influence the interaction between the
protein/peptide and the PSi pore surface. Kaasalainen et al. studied the adsorption of GLP-
1 into PSi NPs [199]. The study demonstrated that for hydrophobic particles, the highest
loading degree was obtained at pH near the isoelectric point (pI) of the peptide. The study
also showed that in the presence of strong interactions between the peptides and the PSi’s
surface, irreversibly and reversibly adsorbed drug layer was formed, as shown in the
schematic representation in Figure 7. The study also highlighted the importance of peptide–
peptide interactions in the pores, as the irreversibly adsorbed layer of the peptide forms a
protective layer that facilitates the easy desorption of the reversibly adsorbed peptides [199].
Figure 7 Schematic representation of peptide loading into PSi, showing irreversible and
reversible peptide adsorption into the pores of PSi.
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Based on the extensive studies on the loading of proteins and peptides into the PSi
particles, PSi has emerged as a suitable protein and peptide delivery system. Furthermore,
recent studies with advanced protein/peptide drug delivery systems based on PSi have also
been reported. For example, Minardi et al. developed a composite microsphere comprising
of poly(lactic-co-glycolic acid) (PLGA) as the outer shell and nanostructured silicon
multistage vector as the core, for temporospatially controlled delivery of growth factors
[24]. After subcutaneous injection to mice, the advanced system was able to retain the
incorporated protein for more than 2 weeks, avoiding burst release. Likewise, Araujo et al.
also developed a multifunctional composite system comprised of CPP and chitosan-
modified PSi or PLGA NPs incorporated in stimuli-responsive polymeric microspheres
[18]. The microsystem was assembled using the microfluidics technique and was aimed at
orally delivering GLP-1. In the study, an enhanced in vitro GLP-1 intestinal permeability
was observed along with high interactions with the intestinal cell lines.
2.9 Colloidal nanoparticles for oral protein and peptide delivery
The use of colloidal carriers, based on either polymeric or lipidic materials, have received a
lot of attention because of their well accepted safety profiles [121]. These nanoparticulate
systems offer several advantages as drug delivery systems, such as the ability to control
their physicochemical properties (e.g., size and charge), surface properties, release kinetics
and site-specific action [102]. Emulsion polymerization, interfacial polymerization,
emulsification evaporation, solvent displacement, salting out, emulsification diffusion, and
desolvation are some of the examples of the preparation techniques used for these NPs [102,
205]. The selection of the preparation technique depends on the nature of the polymer or
lipid used and the drug molecule. Nonetheless, most of these techniques involve heat,
sonication, strong agitation or organic solvents, which can harm the structure of the
encapsulated protein/peptide [88].
2.9.1 Polymeric nanoparticles
With the increase in understanding of the polymer structure and its properties, the diversity
in the number of polymers available have notably escalated. This, in turn, has also helped
in the development of various polymer-based NPs. Polymeric NPs are mainly classified as
nanocapsules (vesicular structure with polymeric shell) and nanospheres (polymeric matrix)
[12, 121, 206]. The ability to control the physicochemical properties of polymeric NPs to
protect the encapsulated protein and peptide, to modulate their release behavior and to
enhance their intestinal absorption, makes the polymeric NPs attractive carriers for proteins
and peptides [88]. Some of the commonly used polymers for oral delivery are chitosan [207,
208], dextran [209], alginate [210], poly(?-glutamic acid) (PGA) [211], hyaluronic acid
[212], poly(lactic acid), PLGA [213], polycaprolactone [214], acrylic polymers [215], and
polyallylamine [88, 216, 217]. With several beneficial properties, the polymeric NPs have
also attracted attention from the pharmaceutical industry with several products under
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preclinical and clinical studies. Some of the developed products are chitosan and PGA based
polymeric nanospheres by NanoMega Medical Corporation (Lake Forest, CA, USA) [218],
insulin-loaded nanospheres composed of patented biodegradable polymer by Aphios Corp.
(Woburn, MA, USA) [219], and insulin-loaded bioadhesive NPs by NOD Pharmaceuticals,
Inc. (San Diego, CA, USA) [220].
PLGA, an aliphatic polyester co-polymer, is one of the most used synthetic polymer for
the oral delivery of insulin [100, 221]. The biocompatible and biodegradable nature of
PLGA along with controlled drug release behavior has led to its widespread application as
an oral protein and peptide delivery system, with several in vitro and in vivo studies
demonstrating its efficiency [222-226]. The most common method to produce PLGA
particles to encapsulate hydrophilic molecules is by the water-in-oil-in-water (w/o/w)
double emulsion method [225]. However, poor drug loading (~1%) and possible drug
degradation due to exposure to organic solvents and high shear stress during the preparation
process are disadvantages associated with this technique.
In a study by Reix et al., PLGA NPs were able to withstand the conditions in the intestine
allowing uptake and absorption of insulin [223]. After duodenal administration, the diabetic
rats showed hypoglycemic effect similar to long acting insulin [223]. To impart the pH
sensitivity to the PLGA NPs, several approaches have been studied, such as the use of the
co-polymer of PLGA and Pluronic F68® [224], encapsulation of PLGA NPs into pH-
sensitive polymers, such as the use of hydroxypropyl methylcellulose phthalate (HPMCP)
and Eudragit RS [222]. The pH-responsive polymer coated NPs showed significant
reduction in the burst release of insulin in gastric conditions, along with prolonged reduction
in the blood glucose levels after oral administration [222]. The interaction of the PLGA with
intestine can be improved by modification of its surface by using different moieties, such as
chitosan, CPPs and targeting moieties. Recently, a multifunctional composite was
developed with PLGA NPs that were modified using chitosan and CPP, and further coated
with an enteric polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS) MF
[18, 213, 227]. The NPs were able to release the loaded peptide GLP-1 only in intestinal
conditions. Additionally, the CPP and chitosan modified PLGA NPs were able to show 5.6-
fold higher interaction with the intestinal cell lines, Caco-2 and HT29-MTX, as compared
to the unmodified NPs. Nonetheless, the efficiency of the system has yet to be proven in in
vivo studies. Despite the large number of in vitro and in vivo studies, PLGA NPs have not
been able to enter the clinical trials for oral protein and peptide delivery.
2.9.2 Lipid-based nanoparticles
Lipid-based carriers include a wide variety of systems, such as simple emulsions, self-
emulsifying systems, liposomes, solid lipid NPs (SLNs), and nanostructured lipid carriers
[136]. Such lipidic carriers have well-known safety profile, with some of them already
established for large-scale production [228]. As compared to other systems, the SLNs have
additional benefits to protect the encapsulated drugs, high stability and controlled drug
release [229]. SLNs are solid lipids stabilized in aqueous solution in the presence of one or
more surfactants. The proteins and peptides loaded in SLNs are mainly prepared by
microemulsion, high-pressure homogenization, solvent evaporation and supercritical fluid
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techniques [230]. The encapsulation and release of proteins and peptides from the SLNs are
governed by several factors, such as the properties of the drug, lipid-matrix composition,
type of surfactant size of NPs, preparation technique and its parameters. However, the SLNs
are often associated with poor drug encapsulation and drug expulsion, which occur due to
the polymorphic transition of lipids during the storage [229, 231].
SLNs composed of cetyl palmitate prepared by w/o/w double emulsion technique have
been used for oral delivery of insulin. In the study, after oral administration, a biphasic
hypoglycemic effect was observed, which was attributed to the biphasic release of insulin
from the SLNs [232]. Another study compared the SLNs and wheat germ agglutinin
modified SLNs containing insulin, both in vitro and in vivo. The study showed that the
lectin-modified SLNs had improved stability and showed higher hypoglycemic effect as
compared to the unmodified SLNs. However, poor bioavailability even after modification
was observed, indicating the need for further development of the system [233]. Recently, a
study reported stearic acid and octa-arginine CPP-modified SLNs for oral delivery of insulin
[234]. Although the SLNs showed only partial protection of the encapsulated insulin against
the enzymes in in vitro conditions, a significant hypoglycemic effect on diabetic rats was
observed after oral administration. Nonetheless, the efficiency of these systems as oral
protein/peptide carriers is yet to be proven in preclinical and clinical studies [234].
2.10 Biofunctionalization of the carrier systems
The first generation of drug delivery systems has shown its clinical applicability by
enhancing the efficacy of several drugs [235]. However, to further improve the therapeutic
efficacy of these drug delivery systems, researchers have explored a wide variety of surface
biofunctionalization techniques and developed multifunctional multistage platforms for
sustained release, targeting, and stimuli responsiveness [156, 195, 235, 236]. In the case of
oral peptide delivery, these functionalities mainly include imparting mucoadhesivity to the
carrier [237], targeting to intestinal cells [238], enhancing cellular interactions [239],
permeation enhancing effect [17], and enteric coating [2, 131, 138, 240].
The following subsections deal with some of the modifications that can be used to
enhance the performance of micro- and nanoparticles as oral protein/peptide delivery
platforms.
2.10.1 Chitosan
Chitosan is a naturally occurring polysaccharide, ?-(14) glucosamine polymer, found in
a certain type of fungi [241]. However, it is mainly derived from deacetylation of chitin,
which is the second most abundant polysaccharide in nature. The structure of chitin and
chitosan are shown in Figure 8 [241, 242].
The deacetylation, usually more than 50% of the entire polymer, is done at varying
degrees and with different molecular weights, which have been known to influence the
physicochemical properties, activity and degradation of chitosan. For example, the low
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molecular weight chitosan with low degree of deacetylation has higher solubility and rate
of degradation [243].
Figure 8 Structure of (A) chitin and (B) chitosan.
Chitosan is a cationic biopolymer with high positive charge density with each
glucosamine residue containing one primary amine. The presence of such large number of
amine groups confers important functional properties to chitosan, such as mucoadhesivity
and permeation enhancement [242]. Chitosan is degraded in human tissues by lysozymes,
with possible involvement of chitinases and acid hydrolysis in the process [244]. Owing to
the biocompatibility and biodegradability, chitosan has been widely considered for drug
delivery applications in the pharmaceutical field, but it has not been approved for this
purpose yet [29]. Instead, chitosan has been approved for dietary applications in Japan, Italy
and Finland [245], and it has also been approved by the FDA for wound dressing purposes
[246]. Arai et al. reported that the lethal dose 50% (LD50) of oral chitosan was >16 g/kg,
which is comparable to sucrose [247]. Furthermore, Sonaje et al. demonstrated that after
oral administration of 100 mg/kg of chitosan-based NPs (80 kDa, 80% degree of
deacetylation) to mice, no signs of oral toxicity were observed [248]. Nevertheless, the
toxicity profile of chitosan can be altered by structural modifications, as despite the safety
of the precursor, modification yields a completely new entity [244].
The mucoadhesive property of chitosan is mainly due to its electrostatic interactions
with mucin, along with hydrophobic interactions and hydrogen bonding in the adhesion
process [249]. The permeation enhancing effect of chitosan was established after the first
reports about its ability to enhance the transmucosal delivery of proteins and peptides across
the nasal epithelia [250], and enhancing the paracellular permeability of 14C-mannitol across
Caco-2 intestinal monolayers [251]. Since then, several in vitro and in vivo studies have
been conducted to establish the permeation enhancing effect of chitosan [8]. The mechanism
of chitosan’s influence on the reversible TJs opening has been evaluated by several studies.
In one of the studies in Caco-2 cell monolayers, chitosan treatment led to a decrease of the
strength of TJ by redistribution of the transmembrane protein CLDN4 from the cell
membrane to the cytosol, leading to its degradation in the lysosomes [252]. The TJs were
recovered later by CLDN4 synthesis. However, the disruption of TJs seems to be a result of
a cascade of reactions as elucidated by Hsu et al. (Figure 9) [253]. Briefly, the electrostatic
interactions between chitosan and integrin present on the cell border lead to clustering,
phosphorylation of focal adhesion kinases and Src tyrosine kinases. This, in turn, leads to
the TJs disruption by redistribution of the CLDN4 transmembrane protein [253]. This
permeation enhancing effect of chitosan is pH-dependent due to the low solubility of
26
chitosan at basic pH (pKa ~6.6) [242]. With the increase in pH, chitosan loses its cationic
nature, and thus, fails to interact with the integrin protein on the cell’s surface, thereby
preventing disruption of the TJs [254]. Conversely, another study reported the influence of
the change in intracellular pH by activation of chloride-bicarbonate exchanger on the
opening of the TJs by chitosan, without any changes in the TJs proteins (CLDN4 and ZO1)
[255].
Owing to its beneficial properties, chitosan based drug delivery systems have been
studied extensively for the oral delivery of proteins and peptides. Besides the use of chitosan
micro- and nanoparticles for oral delivery of proteins and peptides [126, 240, 248, 256],
chitosan polymer has also been used to modify the surface of other NPs to impart the
mucoadhesive and permeation enhancer effects [18, 19, 257]. The use of chitosan to modify
the surface of other NPs would combine the benefits of two systems. For example, Fonte et
al. prepared insulin–loaded SLNs with negatively charged surface, onto which chitosan was
adsorbed, conferring positive charge to the NPs. The chitosan coated SLNs showed higher
insulin permeability across intestinal cell monolayers and showed more pronounced
hypoglycemic effect in diabetic rats as compared to unmodified SLNs [19]. Similarly,
chitosan was used to coat nanoemulsions and lipid NPs, which showed improved oral
absorption of the encapsulated protein and peptide [19, 258]. However, despite the
advantages associated with chitosan-based systems, it is still susceptible for degradation
after exposure to the harsh acidic condition in the stomach.
Figure 9 Schematic representation of signaling mechanism of chitosan-mediated TJs opening
[253].
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2.10.2 Thiolated chitosan
Thiolation of chitosan denotes the modification of the primary amine groups with thiol-
containing molecules, such as cysteine, thioglycolic acid, and 2-iminothiolane [259]. There
are several advantages of thiolated chitosan as compared to the unmodified forms, such as,
enhanced mucoadhesivity due to the formation of disulfide bonds with the mucus
glycoproteins, and in situ gelling because of the pH-dependent inter- and intramolecular
disulfide bonds formation [30, 260] In addition, thiomers have also been shown to have a
permeation enhancing effect. The suggested mechanism for permeation enhancing effect is
based on the formation of the disulfide bond between the cysteine residues on thiomers and
the reduced glutathione presence on the apical mucosa of the intestine [30, 261, 262]. The
reduced glutathione inhibits the enzyme, protein tyrosine phosphatase, which subsequently
leads to phosphorylation of the tyrosine subunits of occludens. This phosphorylation leads
to the opening of the tight junctions, thus, exhibiting the permeation enhancing effect [30].
Moreover, thiolated chitosan has also been reported to inhibit the ATPase activity of p-
glycoprotein in intestine [263, 264].
Because of the abovementioned beneficial properties, thiolated chitosan have been
widely used for the oral delivery of proteins and peptides [265-267]. Recently, thiolated
chitosan-coated liposomes have been shown as an efficient peptide carrier, augmenting the
oral bioavailability of the loaded peptide drug [268]. Another study by Millotti et al. also
showed that after oral administration of chitosan-6-mercaptonicotinic acid NPs, the area
under the curve of the plasma insulin levels were 4-fold higher as compared to unmodified
chitosan NPs [239].
2.10.3 Cell-penetrating peptides (CPPs)
CPPs, also known as Trojan horse peptides, have also attracted a lot of interest, owing to
their ability to enter inside the cells. CPPs, 5–30 amino acid peptide sequences, are known
for their ability to deliver a wide variety of cargos into the cells, such as small molecules,
proteins and peptides, nucleic acids and NPs [269]. Since the first report of use of the human
immunodeficiency virus TAT (Trans-activator of transcription) protein to enhance the
absorption of a protein molecule after an intraperitoneal injection [270], the use of CPPs has
received considerable attention as permeation enhancers for proteins and peptides. Some of
the examples of CPPs exploited for oral delivery of proteins and peptides, besides TAT, are
oligoarginine and penetratin [271]. These CPPs are reported to enhance the intestinal
permeation induced by adsorption to the cell surface glycosaminoglycans [271].
One approach for oral delivery of drugs includes the co-administration of the CPP with
proteins and peptides, either by forming a chemical conjugation between them [272] or by
using a physical mixture [273]. Another approach includes the modification of the surface
on the nanocarriers loaded with proteins and peptides [20]. The latter approach with
modification of the nanosystem can be advantageous as it avoids any alteration to the
structure of the protein and peptide. Liu et al. developed oligoarginine-modified
polyethylene glycol (PEG) PLGA NPs for oral insulin delivery. The nanosystem improved
the hypoglycemic effect and augmented the relative oral bioavailability of insulin, without
28
any signs of histological toxicities in the ileac mucosal membranes [20]. Similarly,
enhanced cellular internalization effect of CPP-modified PLGA NPs have also been
described [274]. CPP has also been used to modify chitosan-based NPs with the aim to
combine both of their effects [18, 275, 276]. Guo et al. showed that TAT and chitosan
derived poly(vinyl alcohol) (PVA) NPs enhanced cellular uptake and transcellular transport
of insulin [275]. Moreover, the TAT- and chitosan-modified PVA NPs were able to display
enhanced hypoglycemic effect in diabetic rats as compared to only chitosan-modified PVA
NPs and unmodified PVA NPs. In addition, the colon specific targeting of the system was
shown by single-photon emission computer tomography of the 99mTc isotope labelled NPs
after oral gavage in minipigs [275].
2.10.4 Enteric coating of nanoparticles
Apart from the modification of the particulate systems to enhance the intestinal
permeability, it is also necessary to protect the encapsulated proteins/peptides against the
harsh conditions of the gastric milieu [10]. Taking advantage of the high pH variations in
the GI tract, pH-responsive systems can be developed to avoid the release of
proteins/peptides in stomach with site-specific release in the small or large intestine. Such
pH-responsive systems can be prepared either by coating the NPs with pH sensitive polymer
or by incorporating such polymers in the system to induce pH responsivity [10, 17, 128].
There are several FDA-approved commercially available pH-responsive polymers, such
as poly(methacrylic acid-co-methyl methacrylate) (Eudragit L, S and F), HPMCP and
HPMCAS [277]. These polymers are insoluble at low pH but are soluble at higher pH. In
the case of HPMCAS, the polymer dissolving pH can be adjusted by altering the amounts
of methoxyl, hydroxypropyl, acetyl and succinoyl groups on the cellulose backbone of
polymer [278]. HPMCAS was originally developed and marketed by Shin-Etsu Chemical
Co., Ltd. (Japan) in 1986 [279]. It is categorized based on the physicochemical properties
in six grades. The F grade represents fine particles and the G grade represents the granular
particles. Additionally, the L, M and H grades are chemically different exhibiting different
solubility at various pH, where L, M and H dissolves at pH ? 5.5, 6.0, and 6.8, respectively
[278, 279]. HPMCAS polymers have been used in several studies to develop pH responsive
systems [280-282].
A number of techniques have been investigated for coating NPs, such as the layer-by-
layer technology [283], physical adsorption [284], supercritical anti-solvent process [285],
and microfluidics [286]. However, this dissertation focuses on a new approach to coat NPs,
known as AFR technology. AFR technology is a simple, single-step method [33]. A
schematic representation of the AFR system is shown in Figure 10. The AFR reactor
consists of a feeding container, an atomizer, a heating tube, a diluter and a sample collector.
The first step involves the input of an aqueous or non-aqueous feed dispersion comprising
of the drug and polymer, or the NPs and polymer, into the feeding chamber. Then, the fed
dispersion is atomized into small droplets in the atomizer, which are then carried to a heated
tubular reactor by the stream of nitrogen gas. Thus, the formed droplets are dried in an
upward stream of nitrogen gas, whilst passing through the heated tube. The temperature and
residence time of the droplets can be easily controlled, thus allowing close control of the
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physicochemical properties of the produced NPs [38, 287]. AFR technology has been
employed to prepare different types of micro- and nanosystems for drug delivery purposes.
Recently, Sapra et al. developed spherical lipid NPs with in situ surface modification using
the AFR technology [288]. The surface modified NPs showed enhanced suspension stability
for up to 30 days, by using minimal amount of surface-active agents [288]. In another study
by Raula et al., stable microparticles were developed for pulmonary delivery of two drugs
with different water solubilities [35]. The intact microparticle was composed of a
nanosuspension of budesonide and salbutamol sulfate with mannitol as bulking agent, and
leucine as coating agent. Thus, the formed microparticles allowed simultaneous delivery of
two drugs and displayed excellent aerosolization properties, exhibiting potential for
inhalation therapy [35]. Moreover, this technology has also been employed to generate solid
state DNA NPs (65125 nm). The DNA content in these NPs was ~10% and was shown to
be stable at room temperature [34].
Figure 10 A schematic illustration of the AFR technology.
AFR technology also has additional benefits for preparing formulations for oral peptide
and protein delivery, such as the possibility to avoid the use of any organic solvents by
preparing the dispersion feed in an aqueous medium. In addition, despite of heat application,
the residence time of the droplets in the heated tube lasts only tens of seconds, thus, avoiding
any heat-associated damage [287]. The simplicity and control afforded by the AFR
technology makes it a potential candidate as a polymeric coating approach for
protein/peptide encapsulated NPs.
In summary, the abovementioned different strategies and modification approaches can
be utilized to develop potential carriers for oral delivery of proteins and peptides.
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3 Aims of the study
Despite decades of time and efforts invested, the development oral protein/peptide delivery
systems is still a major challenge. PSi has been studied extensively for its ability to
efficiently load and deliver different types of cargos, from small molecules to large
biomacromolecules. Hence, taking advantage of the numerous benefits associated with the
PSi system, this dissertation aimed at developing several PSi-based carriers for oral delivery
of insulin and GLP-1, which would be able to overcome the limitations associated with the
oral protein/peptide delivery for the treatment of DM. Several surface modification
approaches to impart mucoadhesivity, permeation enhancement and pH-sensitivity to the
PSi systems were also developed and assessed.
The specific objectives of this dissertation were:
1. To investigate the influence of different surface chemistries of PSi microparticles
and different chitosan modification techniques on the interactions with intestinal
cells and insulin permeability across intestinal Caco-2 and HT29 cell monolayers.
(I)
2. To study and compare several chitosan coated nanocarriers based on polymer, lipid
and PSi on the possibility to load GLP-1 and transport it across the intestinal Caco-
2/HT29-MTX cell monolayers. (II)
3. To fabricate multistage mucoadhesive polymer/PSi nanocarriers using AFR
technology for dual-drug loading and site-specific intestinal delivery, enhancement
of the cellular interactions and augmented intestinal GLP-1 permeation across Caco-
2/HT29-MTX/Raji B cell monolayers. (III)
4. To assess ex vivo the ability of multistage pH-responsive polymers/PSi nanocarriers
loaded with GLP-1 and DPP4 inhibitor to enhance the permeation of GLP-1 across
rat intestinal tissues, as well as to study the nanocarriers’ in vivo behavior in diabetic
rats. (IV)
5. To potentiate the permeation enhancing effect of chitosan-modified PSi NPs by
further surface modifications with L-cysteine and CPP, and, to study the insulin
uptake and transport mechanism across intestinal Caco-2/HT29-MTX/Raji B cell
monolayers. (V)
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4 Experimental
This section summarizes the experimental methods used in this dissertation. A detailed
description of all the materials, equipment and methods used in this work can be found in
the respective original publications (I–V). The primary surface stabilized PSi micro- and
nanoparticles were produced at the Laboratory of Industrial Physics, Department of Physics
and Astronomy, University of Turku, Finland.
4.1 Preparation of micro- and nanoparticles
4.1.1 Fabrication of PSi micro- and nanoparticles (I–V)
A monocrystalline, boron doped p+-type Si 100 wafers of 0.01–0.02 ? cm resistivity were
used to prepare the PSi layers using electrochemical anodization [25]. A schematic
representation of the electrochemical anodization cell used in this work is shown in Figure
6. The electrolyte solution used consisted of 1:1 (v/v) hydrofluoric acid (HF, 38%)–ethanol
solution. The fracture planes in the Si-wafers were created by subjecting the wafer to
repeated and pulsed low/high etching profile. Then, the porous layer was lifted off from the
Si substrate by sharply increasing the etching current to the electropolishing region. The
surface of the PSi were then stabilized by thermal hydrocarbonization by placing the porous
layer into a quartz tube in nitrogen flow (1 L/min) for at least 30 min to remove the residual
moisture and oxygen. Then, an acetylene flow (1 L/min) was added to the nitrogen flow at
room temperature, first for 15 min and then at 500 °C for the next 15 min, whilst maintaining
1:1 (v/v) nitrogen and acetylene flow. The layers were cooled down to room temperature
under nitrogen flow. This process yielded thermally hydrocarbonized porous silicon
(THCPSi) (I). For the undecylenic acid treatment, the THCPSi layers were immersed into
undecylenic acid for 16 h at 120 °C, yielding an undecylenic acid modified THCPSi (I–V)
surface. Publications I–II use UnTHCPSi as an abbreviation for undecylenic acid modified
THCPSi and publications III–V use the abbreviation UnPSi.
To prepare the annealed PSi materials, the as-anodized PSi layers were placed into a
quartz tube under nitrogen flush for 45 min at room temperature followed by placing the
quartz tube containing PSi layers to a 700 °C furnace for 15 min [22, 289]. All the surface
stabilization with thermal hydrocarbonization and undecylenic treatment were performed
after this step to form annealed THCPSi (AnnTHCPSi) and annealed UnTHCPSi
(AnnUnTHCPSi) (I).
Finally, to yield micro- and nanoparticles, the multilayer films were wet milled using
high-energy ball mill (I–V). The particle size fraction collected for the microparticles was
<25 ?m after wet sieving with ethanol (I). The final NPs were obtained by using
centrifugation (II–V).
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4.1.2 Fabrication of polymer- and lipid-based nanocarriers (II)
A modified solvent emulsification–evaporation method based on the w/o/w double
emulsion technique was used to prepare polymeric and lipidic NPs [233]. PLGA 50:50 was
obtained from Purac Biomaterials, Purasorb® PDLG 5004 and Witepsol E85 from Sasol,
Germany. First, the polymer/lipid solution (100 mg/mL) was prepared in ethyl acetate in a
heated water bath. To this solution, 100 μL of GLP-1 solution (2.5 mg/mL) was added and
the primary water-in-oil (w/o) emulsion was prepared by homogenization for 30 s using
Vibra-Cell™ ultrasonic processor (Sonics®, Sonics and Materials, Inc., USA). The primary
emulsion was added to 4 mL of PVA solution (2 %), and again homogenized for 30 s to
form the second w/o/w emulsion. This second emulsion was then added to 7.5 mL of 2%
PVA solution and was left for 3 h under stirring to allow the organic solvent to evaporate.
Empty NPs were prepared by replacement of GLP-1 solution with Milli-Q water and
following the same procedure as mentioned above.
4.2 Surface modification of the particles
4.2.1 Chitosan modification of PSi microparticles (I)
AnnUnTHCPSi microparticles were modified with chitosan by either physical adsorption
or chemical conjugation. For physical adsorption, 5 mg of insulin loaded microparticles
were dispersed in 1 mL of chitosan solution (20 mg/mL in 0.01% acetic acid), and then
stirred for 3 h at room temperature. After that, the microparticles were washed twice with
0.01% acetic acid and Milli-Q water and separated by centrifugation at 4500 × g for 3 min.
For chemical crosslinking of chitosan to the surface of AnnUnTHCPSi NPs,
carbodiimide crosslinker with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and
N-hydroxysuccinimide (NHS) were used. First, 3 mg of microparticles were dispersed in 8
mL of 2-(N-morpholino) ethanesulfonic acid (MES) buffer (pH 5.2) containing EDC/NHS
(molar ratio 1:1.12), and then sonicated to disperse the microparticles and stirred for 2 h in
dark conditions. After 2 h of stirring, 2 mL chitosan solution (6 mg/mL in 0.01% acetic acid
pH 5.2) was added to the activated microparticles and stirred overnight to allow conjugation.
The microparticles were washed similarly to the physical adsorption testing.
After washing, both the NPs were dried overnight at room temperature and the dried
samples were stored at 4 °C until further use.
4.2.2 Chitosan modification of polymeric, lipidic and PSi nanoparticles (II)
Chitosan was physically adsorbed onto the polymeric, lipidic and PSi NPs to modify their
surfaces. For this, 1 mg of NPs were dispersed in 0.5 mL of 1% chitosan solution ( in 1%
acetic acid at pH 5.5) and were allowed to stir overnight at room temperature for deposition
of chitosan on the surface of the particles. The NPs were washed three times using Milli-Q
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water and separated using centrifugation (Optima™ TL, Beckman Coulter, USA). After
washing, the NPs were re-dispersed in Milli-Q water and stored at 4 °C until further use.
4.2.3 Chitosan, L-cysteine and CPP modification of PSi nanoparticles (III–V)
Chitosan was covalently linked to the UnPSi NPs (III–V) using EDC/NHS crosslinking to
form an amide bond between UnPSi and chitosan, forming chitosan-modified UnPSi
(CSUn). For this, 1.5 mg of UnPSi NPs were dispersed in 4 mL of 10 mM MES buffer, and
evenly dispersed by sonicating for 30 s. Then, 8 ?L of EDC (0.877 g/mL at 20 °C) and 6
mg of NHS were added to the dispersion and stirred for 2 h at room temperature in dark to
activate the carboxylic groups of the UnPSi NPs. After activation, the NPs were again tip-
sonicated for 30 s to disperse the NPs properly. To the dispersion, 0.6 mL of 5 mg/mL
chitosan solution (in 1% acetic acid at pH 5.2) were added and stirred overnight to allow an
efficient conjugation to the particles. The NPs were washed three times with Milli-Q water
with subsequent centrifugation to remove the supernatant containing excess of chitosan. The
CSUn NPs were dispersed in Milli-Q water and stored at 4 °C until further use.
L-cysteine and CPP modifications of CSUn NPs were also performed by EDC/NHS
chemistry. 1.5 mg of CSUn NPs were dispersed in 4 mL of 10 mM of MES buffer solution
with 8 μL of EDC and 6 mg of NHS with a final pH of 5.2, and tip sonicated for 30 s. Then,
15 mg of cysteine or 0.5 mg of CPP was added to the dispersion to form cysteine modified
PSi (CYS-CSUn) or CPP modified PSi (CPP-CSUn). The NPs were allowed to mix
overnight at room temperature in dark conditions, and then washed twice with Milli-Q water
with subsequent centrifugation to remove unbound L-cysteine or CPP. The modified NPs
were dispersed in Milli-Q water and stored at 4 °C until further use.
4.2.4 Alexa Fluor 488 modification of PSi nanoparticles (III–V)
Alexa Fluor 488 (AF488) conjugated NPs were used for cellular interaction studies, which
are explained in detail in later sections. First, AF488-conjugated UnPSi NPs were prepared
by surface activation as described in Section 4.2.3. After activation, 21 μg of AF488 was
added to NPs and stirred for 2 h. The NPs were washed once with diluted hydrochloric acid
(0.01 M) and once with water. Then, the AF488-conjugated UnPSi were treated as UnPSi
NPs and further treated with chitosan, L-cysteine and CPP, as described above, to obtain
the corresponding AF488 modified NPs.
4.2.5 Coating by AFR technology (III–IV)
A dispersion consisting of 3 mg of GLP-1 loaded CSUn NPs, 15 mg of HPMCAS-MF
polymer and 2 mg of DPP4 inhibitor solution was prepared, with the total solid content of
0.01% (w/v) at pH 7.4. The NPs dispersion was sonicated for 1 min, and then fed into the
AFR. A collision-type jet atomizer breaks the feed into droplets, which are then suspended
using nitrogen gas (3 L/min), which carries the droplets into the heated laminar flow reactor
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(80 °C). In the reactor, the droplets were dried to complete the formation of HPMCAS-MF
coated CSUn (H-CSUn) [37, 287], which were then collected in a Berner-type low-pressure
impactor [290]. A schematic representation of the AFR technology and the process involved
is shown in Figure 9.
4.3 Physicochemical characterization
The physical properties of the PSi micro- and nanoparticles, such as the pore size and
volume, and the surface area were characterized by nitrogen sorption using a TriStar 3000
gas sorption apparatus. The specific surface area was calculated using the Brunauer-
Emmett-Teller theory from the acquired isotherms and the pore volume was calculated
using the total adsorbed amount at a relative pressure of p/p0 = 0.97 [291]. Additionally, the
average pore diameter was also estimated using the surface area and the total pore volume,
assuming that the pores were cylindrical in shape [21].
The size (z-average) distribution for the NPs and zeta-potential (?-potential) for both
microparticles and NPs were measured using a Zetasizer Nano instrument (Malvern Ltd.,
UK). The surface modification of the prepared systems were confirmed by analyzing dried
micro- and nanoparticles using Fourier transform infrared spectroscopy. The morphology
of the microparticles was investigated using a scanning electron microscope (SEM, Zeiss
DSM 962) after sputter coating with Pt. The NPs were also visualized under transmission
electron microscope (TEM, Tecnai™ F12, FEI Company, USA). The multistage pH-
polymer NPs were evaluated by high-resolution scanning electron microscope (HR-SEM,
Zeiss Sigma, Germany). The H-CSUn NPs were placed on stubs and then sputter coated
with gold before observation under HR-SEM.
4.4 Drug loading and release
4.4.1 Insulin loading and release from PSi microparticles (I) and nanoparticles
(V)
Drug loadings of the micro- and nanoparticles were performed using an immersion
technique [25]. For microparticles, 1.25 mg of microparticles were dispersed in an insulin
solution (5 mg/mL in 0.01 M of HCl) and were mixed for 90 min at room temperature. The
microparticles were then centrifuged to remove the excess of unloaded insulin. The
supernatant was used to quantify the amount of unloaded insulin by high performance liquid
chromatography (HPLC) (I). For the chitosan-adsorbed particles, the loading was
performed before the surface modification, whereas for the chitosan-conjugated particles,
the loading was performed at the end following the same protocol. The drug loading was
calculated using Eq. (1):
Insulin was loaded into the modified NPs by first dispersing 200 μL of NPs (2 mg/mL)
into 900 μL of insulin solution (200 μg/mL), followed by stirring at room temperature for
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90 min. The NPs were centrifuged to remove the excess of insulin and washed once with
Milli-Q water. The drug loading was calculated using Eq. (1).
Eq. (1)
The in vitro release profiles of insulin from the modified NPs were investigated by
dispersing the NPs equivalent to 35 μg of insulin in 10 mL simulated gastric fluid (SGF,
without pepsin) for the first 2 h. Then, the NPs were removed from the medium by
centrifugation and reintroduced in 10 mL of fasted state simulated intestinal fluid (FaSSIF)
for the next 6 h. Samples were withdrawn at different time intervals, and the volume was
replaced with fresh pre-warmed medium after each withdrawal. HPLC was used to quantify
the amount of insulin released over time (V).
4.4.2 GLP-1 loading and release studies from polymeric, lipidic and PSi
nanoparticles (II)
In the case of polymeric and lipidic NPs, GLP-1 was loaded during the particle’s preparation
step as described in Section 4.1.2. For PSi NPs, 1 mg of the NPs was dispersed in solution
containing 200 μg of GLP-1. The dispersion were stirred for 90 min at room temperature,
and then centrifuged after that to remove the excess amount of GLP-1. Chitosan coating
was performed onto PSi NPs after the loading process. GLP-1 loading was evaluated by
quantifying the amount of GLP-1 in the supernatant for all the three NPs (II).
For the release study, the amount of NPs corresponding to 30 μg of GLP-1 was first
dispersed in pH 1.2 buffer for 2 h and then was transferred to FaSSIF for the next 4 h, to
simulate the passage of the NPs in the GI tract. The experiment was performed at 37 °C and
the samples were withdrawn at different time points followed by replacement with fresh
pre-warmed release media. The samples were centrifuged and then the supernatants were
analyzed in HPLC to quantify the amount of GLP-1 released (II).
4.4.3 GLP-1 and DPP4 inhibitor loading and release from polymer-coated PSi
nanoparticles (III–IV)
GLP-1 was loaded into the pores of UnPSi and CSUn NPs, and DPP4 inhibitor was
encapsulated in the polymeric matrix coating (III and IV). 1 mg of NPs were dispersed in
1.5 mL of GLP-1 solutions (133 μg/mL), which were magnetically stirred for 90 min at
room temperature. After loading, the NPs were centrifuged to remove the excess of GLP-1.
The loading degree for GLP-1 was calculated using Eq. (1). For DPP4 inhibitor, 1 mL of
the inhibitor solution (1 mg/mL in Milli-Q water) was added to 6 mL of HPMCAS-MF
Loading degree (%) =
Initial amount of drug added (g) - Free unloaded drug (g)
Weight the particles (g)  100%
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solution. The final polymer coated NPs was dissolved in phosphate buffer (pH 7.4) to
determine the loading degree of DPP4 inhibitor.
The in vitro release behaviors of GLP-1 and DPP4 inhibitor were studied by dispersing
the NPs in two different release media: 10 mL of pH 1.2-buffer solution for 2 h and 10 mL
of FaSSIF (pH 6.8) for 6 h at 37 °C. For the GLP-1 release studies, the amount of NPs
equivalent to 30 μg of GLP-1 was used, and for the DPP4 inhibitor release study, NPs
corresponding to 30 μg of DPP4 inhibitor were used. The sample aliquots were collected at
different time points, and were replaced by fresh pre-warmed buffer. The samples were
immediately centrifuged, and the aliquots were analyzed by HPLC (III).
4.5 In vitro cell based studies
4.5.1 Cell lines and cell culturing (I–III, and V)
Human colon adenocarcinoma Caco-2, goblet cells HT29, lymphocytes Raji B, and human
gastric adenocarcinoma AGS cells were obtained from American Type Culture Collection
(USA). Goblet-like HT29-MTX was kindly provided by Dr. T. Lesuffleur (INSERM U178,
Villejuif, France). All the used cell lines were cultured in Dulbecco's Modified Eagle’s
Medium (DMEM), except the AGS cells that were cultured in Roswell Park Memorial
Institute (RPMI) medium. All the cell cultures were kept in a standard incubator (16 BB
gas, Heraeus Instruments GmbH, Germany) at 37 °C in an atmosphere of 5 % CO2 and 95
% relative humidity. Both media were supplemented with 10% heat inactivated fetal bovine
serum, 1% non-essential amino acid, 1% L-glutamine, penicillin (100 IU/mL) and
streptomycin (100 mg/ml). The growth medium was changed every other day for all the cell
lines used until the end of the experiments, and the subculturing performed at 80%
confluency. The adherent cells were passaged using trypsin-PBS-EDTA.
4.5.2 Cytotoxicity
For the cytotoxicity studies, cells were first seeded into 96-well plates (Corning Inc., USA).
Caco-2 and HT29 cells were seeded at a cell density of 1 × 106 cells/mL (I), and AGS, Caco-
2 and HT29-MTX were seeded at a cell density of 5 × 105 cells/mL (II–V). The cells were
allowed to attach for 24 h, and were washed with Hank's balanced salt solution (HBSS)–2-
(4-(2-hydroxyethyl) piperazin-1-yl) ethanesulfonic acid (HEPES) buffer (pH 7.4) before
adding the particles. 100 μL of the particle dispersions in HBSS–HEPES buffer were added
to the wells and were incubated for 3 h for AGS cells (III) and 12 h for the intestinal cells
(I–V) at 37 °C. After incubation, the cells were washed once with fresh HBSS–HEPES
buffer. Next, 100 ?L of CellTiter-Glo® reagent assay (Promega Corporation, USA) pre-
diluted with HBSS–HEPES buffer (2) were added to the wells. A positive (1% Triton X-
100) and negative control (HBSS–HEPES buffer solution) were prepared and treated
similarly to the sample wells. The luminescence was measured using Varioskan Flash
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Multimode Reader (Thermo Fisher Scientific, USA). All the experiments were carried out
at least in triplicate (n?? 3).
4.5.3 Cell–particle interactions
The cell–particle interactions were evaluated qualitatively by confocal fluorescence
microscopy and TEM imaging, and quantitatively by flow cytometry. Fluorescein
isothiocyanate (FITC)-insulin loaded microparticles (I), FITC loaded NPs (II) or AF488-
conjugated NPs (III and V) were used for the interaction studies with Leica SP5 confocal
fluorescence microscopy (Leica Microsystems, Germany).
For confocal studies, intestinal cells either as co-cultures (I–III) in a ratio of 9:1 (Caco-
2:HT29/HT29-MTX) or as monocultures (III) were seeded in Lab-Tek™ 8-chamber slides
(Thermo Fisher Scientific, USA), and were allowed to attach for 24 h. The cells were then
washed with pre-warmed buffer; 200 μL of particles (250 μg/mL) were added to the cells,
and incubated for 3 h at 37 °C. After the end of incubation period, the cells were washed
twice with fresh HBSS–HEPES buffer. The plasma membranes were stained by incubating
the cells with 200 ?L of CellMask™ Orange (InvitrogenTM, USA) for 3 min at 37 °C. The
excess of staining solution was washed twice with fresh HBSS–HEPES buffer and the cells
were fixed by incubating with 2.5% glutaraldehyde for 20 min at room temperature. The
intracellular localization of the particles was then observed by confocal fluorescence
microscope. A triple co-culture cell monolayer composed of Caco-2/HT29-MTX/RajiB
cells (90:10:1) was used to study the cell–particle interactions (V) [292, 293]. The NPs were
incubated with the cell monolayers for 3 h at 37 °C. After incubation, the cell monolayers
were washed with the fresh HBSS–HEPES buffer and the glycoproteins stained with wheat
germ agglutinin (WGA) labelled with Alexa Fluor 594 (10 μg/mL) for 10 min at 37 °C. The
cell monolayers were immediately observed under confocal fluorescence microscope,
where z-stack images were taken and later analyzed with Imaris software (Bitplane, USA)
to develop 3D images.
For the TEM imaging analysis, the particles were incubated with cell monolayers for 3
h at 37 °C, and then washed twice with HBSS–HEPES buffer. The cell monolayers were
fixed with 2.5% glutaraldehyde for 20 min at room temperature, and washed twice with
sodium cacodylate buffer for 3 min. Next, the cell monolayers were post-fixed with 1%
osmium tetroxide in 0.1 M NaCac buffer (pH 7.4), and dehydrated and embedded in epoxy
resin. Ultrathin sections (60 nm) were cut perpendicularly to inserts, post-stained with
uranyl acetate and lead citrate, and examined under TEM (Tecnai™ F12, FEI Company,
USA).
For quantitative analysis of the cell–particle interactions, flow cytometry studies (III
and V) were conducted. The intestinal cells were first seeded in 6-well plates at a density
of 7 × 105 cells/well and incubated at 37 °C for two overnights. The cells were washed once
with HBSS–HEPES (pH 7.4) buffer. Next, 1.5 mL of particles of AF488-conjugated NPs
were added to the cells and incubated for 3 h at 37 °C. After incubation, the cells were
washed twice with the buffer and detached with trypsin-EDTA (III) or Versene (V). After
detaching, the cells were once again washed with the buffer, suspended in 700 ?L of buffer
and measured with Gallios Flow Cytometer (Beckman Coulter, USA) with an excitation
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laser wavelength of 488 nm. For each sample, ca. 10,000 events were recorded, analyzed,
and plotted using Kaluza Analysis Software v1.3 (Beckman Coulter, USA).
4.5.4 Cellular intestinal permeability
For evaluating the intestinal permeability of insulin and GLP-1, two different cellular
intestinal models were prepared. For the first study, Caco-2/HT29 (I) co-culture monolayers
were prepared. 500 μL of cells (1.5 × 105 cells/mL) were seeded in 12-well cell culture
inserts (Transwell®, Corning, USA), with the cell medium replaced every other day until
the cell monolayer was formed after 21–22 days. For the other studies (II, III and V), Caco-
2/HT29-MTX/RajiB triple co-culture cell monolayers were prepared. In this model, Caco-
2 and HT29-MTX were seeded as the cell co-cultures described above, and maintained until
14 days. Then, RajiB cells (1 × 105 cells/well) were added to the basolateral chamber and
the cell monolayers were maintained for the next 7 days. Raji B was added to induce M cell
phenotype in Caco-2 cells in the monolayer [292]. During the permeability studies, the cell
monolayers were first washed twice with HBSS–HEPES buffer and then 0.5 mL of the
particle dispersion were added to the apical chamber. The plates were then incubated at 37
°C for 3 h with shaking at 100 rpm. Samples (200 μL) were withdrawn from the basolateral
chamber at different time intervals, and then replaced with fresh pre-warmed buffer each
time to maintain constant medium volume during the experiments. Insulin was quantified
using a human insulin Enzyme-Linked Immunosorbent Assay (ELISA) kit (Mercodia,
Sweden), GLP-1 was quantified using a GLP-1 Enzyme Immunoassay (EIA) kit (Sigma
Aldrich, USA), and DPP4 inhibitor was quantified using HPLC. The activity of the DPP4
enzyme was analyzed using a DPP4 assay kit (Sigma–Aldrich, USA) to confirm the enzyme
inhibition after the exposure to the DPP4 inhibitor.
4.5.5 Cellular intestinal uptake and transport mechanism (I and V)
The cellular uptake of FITC-insulin loaded PSi microparticles were studied with Caco-
2/HT29 cell monolayers (I). PSi microparticles were added to the apical side of the
monolayer and the HBSS–HEPES buffer was added to the basolateral chamber. The
particles were then incubated with the cell monolayer at 37 °C for 3 h with shaking at 100
rpm. Then, the cells were first washed, lysed using a cell-lysing buffer, and then the lysate
was centrifuged to remove the supernatant. The supernatant was used to quantify the amount
of insulin interacting with the cells and the mucus layer by using a Varioskan Flash
Multimode Reader.
The cellular uptake and transport mechanism studies were also performed in a triple co-
culture intestinal cell monolayer model (as described above) for the L-cysteine- and CPP-
modified CSUn NPs (V). Firstly, the cell monolayers were washed and equilibrated with
the buffer for 15 min at 37 °C. Then, 0.5 mL of NPs (250 μg/mL) were added to the apical
chamber under different conditions and also in the presence of several inhibitors: (i) 4 °C
(ii) 100 mM of sodium azide (iii) 1 mM of protamine (iv) pre-incubation with 35 mM of
sodium chlorate for 48 h and rinsed twice with HBSS–HEPES buffer and incubated with
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the NPs dispersion (v) chlorpromazine (10 μg/mL) (vi) fillipin (1 μg/mL) and (vii) controls
without any inhibitor. All the inhibitors were added with the NPs and incubated with the
cell monolayers for 3 h at 37 °C [238]. After the incubation period, the amount of insulin in
the basolateral chamber was quantified for all the tested conditions using a human insulin
Elisa Kit (Mercodia, Sweden). The results are shown as percentages compared to controls
(without any inhibition denotes 100%). The cell monolayers were then washed three times
with ice-cold HBSS–HEPES buffer, including a wash with 5 mM of EDTA solution to
remove the adhering NPs. The cells were lysed by incubating with the cell lysis buffer, and
then the lysate was centrifuged at 4000×g for 5 min. The supernatants were analyzed to
quantify insulin. The cell associate proteins were also analyzed in the lysate using a Pierce™
BCA Protein Assay Kit (Thermo Fischer Scientific, USA). The uptake results are shown as
the percentage of the control of insulin associated per mg of cell protein.
4.6 Ex vivo permeability and intestinal adhesion studies (IV)
Ex vivo permeability of GLP-1 and DPP4 inhibitor across healthy rat ileum were studied
using a ligated intestinal method as described by Yin et al [126]. A freshly excised small
intestine of rat was cleaned using Kreb’s ringer buffer, and sections of ca. 5 cm were cut,
with one end closed using a thread. Then, H-CSUn NPs containing 50 μg of GLP-1 and 180
μg of DPP4 inhibitor dispersed in 0.5 mL of Kreb’s-Ringer buffer was placed into the
intestinal loop. The loop was closed by tying the open end with silk thread to form a closed
sac. As a control, 0.5 mL of solution containing GLP-1 (100 μg/mL) and DPP4 inhibitor
(360 μg/mL) in pre-oxygenated Kreb’s-Ringer buffer was used. The filled intestinal sacs
were washed several times with pre-oxygenated Krebs-Ringer buffer, and then immersed in
container with 10 mL of Kreb’s ringer buffer at 37°C with smooth shaking. The buffer was
aerated throughout the experiment with 95% oxygen and 5% carbon dioxide. Samples (200
μL) were withdrawn from serosal side at regular time intervals (up to 3 h) and the withdrawn
volume was replaced subsequently with pre-warmed fresh buffer. The GLP-1 content was
analyzed using GLP-1 EIA Kit (Sigma-Aldrich, USA), and DPP4 inhibitor was quantified
by using HPLC method.
For the intestinal adhesion studies, the same protocol as for the permeability study was
used, but instead of drug loaded NPs, AF488-conjugated NPs were added to the intestinal
loop. After the incubation of the loops in Kreb’s ringer buffer at 37 °C with gentle shaking
for 3 h, they were washed twice with the buffer and small sections of the intestinal tissues
were cut. The tissues were then fixed and stored in 4% paraformaldehyde at 4 °C. The
tissues were embedded in paraffin, and small sections (5 μm) were cut and placed onto a
glass slide. The sections were dewaxed and rehydrated, and stained with WGA-conjugated
AlexaFluor 594 (10 μg/mL) for 10 min at room temperature. DAPI (4’, 6-diamidino-2-
phenylindole, dihydrochloride) (300 nM) was used to stain the nuclei of the cells by
incubating with the cell monolayers for 4 min at room temperature. The tissues were again
washed with buffer and the coverslips were mounted on the tissue sections. The slides were
immediately observed under confocal fluorescence microscope.
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4.7 In vivo study (IV)
4.7.1 Animal model
Animal experiments were approved by the Local Ethics Committee at the University of
Porto and conducted under the guidelines and recommendations of FELASA and the
European Directive 2010/63/EU. To evaluate the in vivo behavior of the H-CSUn NPs, adult
Wistar rats (7 weeks old), weighing 180–200 g were purchased from Harlan Laboratories,
Inc. The animals were housed in groups of 5 in standard conditions (temperature of 22 ± 2
°C, with relative humidity of 35% to 60% and 12 h light/dark cycles) with standard pellet
food and water ad libitum. The rats were induced with T2DM prior to the main experiment.
For this, the animals were fasted for 16 h, and then they were intraperitoneally (i.p.) injected
with nicotinamide (120 mg/kg), followed by i.p. injection of streptozotocin (60 mg/kg) after
15 min. The T2DM induction was established by the raise in the blood glucose levels after
72 h [294-296].
4.7.2 In vivo evaluation after oral administration of the
nanoparticles
The T2DM rats were fasted for 16 h before administration of the NPs. A number of
formulations were administered via oral gavage, namely: (1) GLP-1 and DPP4 solution (2)
empty H-CSUn NPs and (3) GLP-1 and DPP4 inhibitor loaded H-CSUn NPs. The amount
of NPs administered were corresponding to 250 μg/kg of GLP-1 to the weight of the rats,
using the gavage solution corresponding to 6.4 mg/mL of H-CSUn NPs. The NPs were
dispersed in citrate buffer (pH 4) to avoid premature release of the drug in the stomach.
Blood samples were withdrawn from the tail vein of the animals at different time intervals.
Blood glucose levels were measured for 8 h using a glucometer, and the percentage of
decrease in the blood glucose levels (%) were calculated using Eq. (2).
Eq. (2)
In the Eq. (2), AUC (control) is the area under the curve of the blood glucose levels after
oral administration of the control solution of GLP-1 and DPP4 inhibitor or empty NPs
without any drugs and AUC (Nanoparticles) indicates the area under the curve of blood
glucose levels after oral administration of H-CSUn NPs with GLP-1 and DPP4 inhibitor.
The plasma DPP4 levels were also measured with HPLC after extraction with acetonitrile.
Decrease in blood glucose levels (%) =
AUC (Control) - AUC (Nanoparticles)
AUC (Control)
 100%
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5 Results and discussion
Particulate-based drug delivery systems with the ability to efficiently encapsulate and
release proteins/peptides, protect against the harsh conditions of the gastric milieu, and
enhance the intestinal drug permeability, hold a great potential for oral protein/peptide
delivery. In this context, the potential of polymer, lipid and PSi based micro-/nanosystems
as carriers for oral insulin and GLP-1 delivery were evaluated. Further modifications with
different biofunctional moieties and encapsulation in the polymeric matrix were also
performed, to impart several advantageous properties to the system, such as
mucoadhesivity, cellular uptake, pH-responsivity and permeation enhancing property.
Furthermore, the mechanism of uptake and transport of insulin from such systems with in
vivo efficacy were also investigated.
5.1 Influence of surface chemistry and chitosan modification of
PSi microparticles (I)
The properties of microparticles, such as surface charge, surface chemistry and presence of
surface functional groups, can greatly influence the potential as drug delivery systems by
affecting the ability to load drug molecules and/or their cellular interactions [22, 297].
Therefore, the focus of the first study was to evaluate the influence of the surface chemistry
of PSi microparticles and the different approaches for chitosan surface modifications on
insulin loading, interactions with intestinal cells, and permeability across intestinal cell
monolayers. Hydrophobic AnnTHCPSi and slightly hydrophilic –COOH terminated
AnnUnTHCPSi microparticles were compared, together with the evaluation of two different
techniques of chitosan modifications of AnnUnTHCPSi: physical adsorption and chemical
conjugation.
5.1.1 Insulin permeability and uptake across intestinal cell monolayers
The poor intestinal permeability of orally administered proteins and peptides is mainly due
to the presence of the viscous mucus layer covering the epithelial cells and the TJs present
between the adjacent intestinal epithelial [100]. Therefore, it is essential to evaluate the
impact of the oral protein/peptide delivery systems on intestinal permeability of
encapsulated protein/peptide. In this study, cell monolayers composed of enterocyte like
Caco-2 and mucus producing HT-29 cells were used as a model for the intestinal epithelium.
This model resembles intestinal epithelium more closely and overcomes the limitations of
Caco-2 monolayers, such as tightness of the monolayers that resembles the colonic
conditions, lack of mucus layer, comprised of only absorptive cells, and over-expression of
P-glycoprotein [16, 292].
The permeability profiles of insulin from different microparticles are shown in Figure
11A. It can be clearly seen that bare AnnTHCPSi and AnnUnTHCPSi microparticles were
able to enhance the permeability of insulin across the cell monolayers, with enhancement
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ratios (ER) of 2.54 and 1.47, respectively, as compared to insulin solution. AnnTHCPSi
microparticles showed better insulin permeation enhancing effect than AnnUnTHCPSi
Figure 11 (A) In vitro permeability profiles of insulin-loaded PSi microparticles across Caco-
2/HT-29 co-culture monolayers. All the experiments were conducted from the apical
(pH 6.5) to basolateral direction (pH 7.4) in HBSS–HEPES buffer at 37 °C. (B) Amount
of FITC-insulin attached or taken up in Caco-2/HT-29 co-culture monolayers.
Statistical analysis was made by the Student’s t-test and all the data were compared to
pure insulin. The level of significance was set at a probability of **p < 0.01. Error bars
represent standard deviation (n = 3). Copyright © (2014) Elsevier B.V., reprinted with
permission from publication (I).
Furthermore, the highest insulin permeation across the monolayers was observed when
chitosan was chemically conjugated to AnnUnTHCPSi microparticles, with an ER of 7.62.
This augmented transport of insulin could be attributed to the presence of mucoadhesive
chitosan present on the surface of the microparticles. Additionally, chitosan has also been
reported to temporarily open the TJs between the intestinal epithelial cells thereby
improving the intestinal insulin permeability [28, 244, 259]. Thus, modifying the surface of
negatively charged PSi with chitosan renders the particles an additional advantage, which
augments the insulin permeation across the intestinal cell monolayers. However, the
chitosan adsorbed AnnUnTHCPSi microparticles did not demonstrate any permeation
enhancing effect on insulin. This deteriorating effect can be due to the insulin loading, which
occurs prior to chitosan coating, unlike chitosan conjugated AnnUnTHCPSi, where the
loading was performed after the surface modification. The additional steps during chitosan
adsorption and subsequent washing can lead to possible loss of insulin.
Uptake of insulin from these microparticles was also studied in the cell monolayers,
which is shown in Figure 11B. The uptake results showed that the highest amounts of
insulin associated with the cells and mucus were found with the chitosan-conjugated
AnnUnTHCPSi, (p < 0.01), followed by the AnnTHCPSi microparticles, which
corroborates with the permeability results. Overall, it was observed that the difference in
surface chemistry of PSi microparticles influenced the insulin permeation across the cell
monolayers, with the highest permeation effect observed for the chitosan-conjugated PSi
microparticles.
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5.1.2 Interaction of PSi microparticles with the intestinal cells
Possible interactions between the PSi microparticles and the intestinal cells (Caco-2 and
HT29) were evaluated qualitatively by confocal fluorescence microscopy, Figure 12. The
images clearly showed that there were minimal interactions between the unmodified
particles and the cells, whereas the chitosan-modified PSi particles showed significant
interactions with the cells. The poor interaction between the AnnTHCPSi and
AnnUnTHCPSi microparticles can be explained by the negative surface charge, which can
lead to repulsion from the negatively charged mucus layer and cell membranes [108].
Conversely, the chitosan-modified microparticles exhibited substantial interactions with the
intestinal cells, which can also be attributed to the cationic charge and mucoadhesivity
inherited by the presence of polycationic chitosan on the particle’s surface [249]. The
confocal images also showed higher cellular interactions with the chitosan-conjugated
microparticles, as compared to the chitosan-adsorbed particles. The higher cell–particle
interactions can be due to the presence of higher amounts of chitosan on the surfaces of the
particles when chemically conjugated (11.7 ± 1.0 w-%), as compared to physical adsorption
(1.1 ± 0.8 w-%).
Figure 12 Confocal microscope images of Caco-2/HT-29 co-culture monolayers treated with
different PSi microparticles (400 ?g/mL) loaded with FITC-labeled insulin after
incubation with the cells at 37 °C for 3 h. Red: cell membranes stained with CellMaskTM
Orange; green: FITC-labeled insulin; yellow: co-localization of PSi microparticles
and the cell membranes. Copyright © (2014) Elsevier B.V., reprinted with permission
from publication (I).
In conclusion, these results showed that the insulin permeation across intestinal cell
monolayers could be enhanced by incorporating the insulin into the pores of the
AnnTHCPSi microparticles. Additionally, the chitosan surface modification of
AnnUnTHCPSi particles via chemical crosslinking showed the most efficient surface
modification, leading to an enhanced intestinal insulin permeability, cellular uptake of
insulin, and augmented cellular interactions.
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5.2 Chitosan-modified nanoparticles as oral carriers for GLP-1 (II)
Different nanocarrier systems offer different advantages that can be beneficial for oral
delivery of proteins and peptides. Thus, in the second study, a comparative analysis between
nanocarriers composed of three different biomaterials, polymeric PLGA NPs, SLNs and
UnTHCPSi NPs, were performed to evaluate their ability to deliver GLP-1 orally. The
surface of all the nanosystems were modified with chitosan by physical adsorption
(UnTHCPSi + CS, PLGA + CS, SLN + CS). These nanosystems were compared on the
basis GLP-1 loading efficiency, in vitro release behavior, cellular interactions, and intestinal
permeation of GLP-1.
5.2.1 GLP-1 encapsulation and in vitro release behavior
The physicochemical characterization of PLGA, SLNs and UnTHCPSi NPs presented a
particle size of ~200 nm and a negative surface charge for all the NPs. After chitosan
adsorption, a slight increase in the particle size was observed with conversion of the surface
charge from negative to positive, indicating successful surface modification of the NPs. The
GLP-1 loading evaluations showed that the UnTHCPSi NPs encapsulated the highest
amount of GLP-1 with a loading degree of 17% (w/w), whereas the PLGA NPs and SLNs
displayed a loading degree of only 0.17 % (w/w) and 0.18 % (w/w), respectively. The
observed variances in the loading degree can be attributed to the loading technique used and
the structure of these NPs. In the case of PSi NPs, the porous nature and the use of physical
adsorption of the peptide into the pores of the NPs allowed the incorporation of high
payloads [151]. However, the solid matrix based structure of PLGA NPs and SLNs limit the
space available to encapsulate drug molecules. Additionally, the encapsulation of GLP-1
during the preparation steps also increases the probability of losing peptide during the
multiple preparation step processes [298]. Nonetheless, after chitosan adsorption, a slight
decrease in the loading degree was observed for all the NPs, which can be attributed to the
loss of encapsulated GLP-1 during the coating process.
The nanocarriers were also evaluated based on the in vitro GLP-1 release behavior in
simulated GI conditions. For this, the NPs were first exposed to pH 1.2 solution for 2 h
mimicking the gastric conditions, and the next 4 h in FaSSIF to simulate the intestinal
conditions. The GLP-1 release profiles of the unmodified and chitosan-modified NPs are
shown in Figures 13A and 13B, respectively. The release profiles showed that the SLNs
did not retain the encapsulated GLP-1 in acidic conditions, with a burst release of 68%, and
degradation of GLP-1 over time. The burst release observed for SLNs can be due to the
hydrophilic nature of the peptide, which tends to accumulate at the o/w interface during the
fabrication process [230, 299, 300]. UnTHCPSi and PLGA NPs sustained the release of
GLP-1 to some extent in the acidic conditions, with burst GLP-1 release in simulated
intestinal conditions. This biphasic GLP-1 release behavior from the PLGA and UnTHCPSi
can be explained by the nature of their interactions with GLP-1 (pI = 5.4). At acidic
conditions, GLP-1 carries a net positive charge and tends to interact strongly to the
negatively charged particles. However, the charge of GLP-1 in basic intestinal conditions is
negative, which leads to minimal interactions with the NPs due to charge repulsion [196,
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301]. The chitosan coated NPs depicted a more sustained release of GLP-1 in both
conditions, despite similar release patterns (Figure 13B). These results are in accordance
with other reports where chitosan has been shown to decrease the burst release of the drugs
encapsulated in NPs [299].
Figure 13 Release profiles of GLP-1 from (A) PLGA NPs, SLNs and UnTHCPSi NPs and from
(B) PLGA + CS, SLN + CS and UnTHCPSi + CS NPs. The percentages of peptide
released from uncoated NPs were compared with their corresponding CS-coated NPs
at the same time points, and compared with the other NPs. All experiments were
conducted at pH 1.2 for the first 2 h and in FaSSIF (pH 6.5) for the next 4 h at 37 °C
and 100 rpm. Error bars represent the mean ± SD (n = 3). Copyright © (2014) Elsevier
B.V., reprinted with permission from publication (II).
Overall, it was observed that PLGA and UnTHCPSi NPs averted the release of GLP-1
in gastric conditions to some extent, with higher GLP-1 release at intestinal conditions.
Furthermore, it was also shown that after chitosan coating, the NPs suppressed the
premature release of GLP-1 in gastric conditions and released it in the intestinal medium.
5.2.2 Intestinal transport of GLP-1 from chitosan-coated nanoparticles
From the release studies, it was evident that the chitosan coated NPs improved the GLP-1
release behavior, as compared to the unmodified NPs. Hence, the permeability of GLP-1
across cellular intestinal monolayers was only assessed for the chitosan-modified NPs. For
this, triple co-culture cell monolayers were used as the intestinal cell model. The monolayers
comprised enterocytes (Caco-2 cells), mucus-producing goblet cells (HT29-MTX), and M
cells, which were induced from Caco-2 cells in the presence of Raji B cells [293]. All the
three cell types together formed a monolayer with TJs that resemble the intestinal epithelium
more closely [293, 302].
The GLP-1 permeability profiles from the different chitosan modified nanosystems are
shown in Figure 14A. Among the different systems, free GLP-1 solution exhibited the
highest permeation across the cell monolayers, which can be explained by the presence of
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high amounts of free peptide in the apical side as compared to the NPs, where only partial
amount of total GLP-1 was released. Additionally, the release of GLP-1 from the different
NPs would have been even more sustained in HBSS–HEPES as compared to FaSSIF,
because of the absence of natural surfactants, such as bile salts, in the buffer solution.
Comparing the NPs, the PSi NPs showed the highest GLP-1 permeation, followed by SLNs
and PLGA NPs. These results are in accordance with the in vitro release studies (Figure
13) that displayed the maximum sustained GLP-1 release behavior from PLGA + CS NPs,
thus having the least amount of peptide available to permeate across the cell monolayers.
Nevertheless for SLN + CS, although GLP-1 showed higher permeation effect as compared
to PLGA + CS NPs, the GLP-1 release profile must be taken into consideration as there is
a loss of ~ 40% GLP-1 in the gastric conditions before reaching the intestinal environment.
Figure 14 (A) In vitro cumulative permeability profiles of GLP-1 from CS-coated NPs across
Caco-2:HT29-TX: Raji B co-culture monolayers. All experiments were conducted from
the apical (pH 6.5) to the basolateral direction (pH 7.4) in HBSS at 37 °C. Error bars
represent mean ± SD (n = 3). (B) TEM images of flat embedded ultrathin sections after
permeability showing control cells (1), PLGA + CS NPs (2), SLN + CS NPs (3), and
UnTHCPSi + CS NPs (3). Copyright © (2014) Elsevier B.V., reprinted with permission
from publication (II).
The GLP-1 transport observed can be attributed to the presence of mucoadhesive
chitosan present on the surface of the NPs. The cell monolayers were examined under TEM
to visualize any possible interactions with the NPs. In the TEM image in Figure 14B, it was
possible to observe that the chitosan modified NPs were closely interacting with the
intestinal epithelium. This interaction with the intestinal cell monolayer can be due to the
positive charge of the particles imparted by the chitosan surface modification. These results
are in agreement with other studies in the literature, which have exhibited similar increase
in interactions between the positive surfaces and the negative charge moieties of the cell
membrane leading to enhanced cellular interactions [156, 303]. The mucoadhesive
properties of the NPs and enhanced GLP-1 permeation across the cell monolayers can
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improve the GLP-1 intestinal absorption, and thus, can possibly improve its oral
bioavailability [304].
Overall, the results of this study showed that for oral GLP-1 delivery, each nanosystem
offered different advantages: high loading and permeation enhancing effect for PSi-based
NPs, sustained drug delivery for PLGA NPs and comparatively better GLP-1 permeability
for SLNs.
5.3 Multistage pH-responsive polymer-PSi delivery systems for
GLP-1 and DPP4 inhibitor (III–IV)
In addition to the physical barrier posed by the intestinal membrane, the biochemical barrier
comprising the highly acidic gastric environment and abundant digesting enzymes present
along the GI tract, may act as one of the major hurdles for oral delivery of proteins/peptides
[300]. Therefore, with the aim to overcome these hindrances, a multifunctional site-specific
dual protein-drug delivery nanosystem was developed to co-deliver GLP-1 and DPP4
enzyme inhibitor orally. Briefly, the nanosystem comprised of chitosan-modified PSi NPs
(CSUn) with GLP-1 loaded in their porous structure. The NPs were then coated with a pH-
responsive polymer using AFR technology, which prevented premature release and
degradation of GLP-1 in the gastric conditions, and provided a site for encapsulation of
DPP4 inhibitor [21]. In this study, undecylenic acid modified thermally hydrocarbonized
PSi (abbreviated as UnPSi), were modified with chitosan by chemical crosslinking, and then
coated with an enteric polymer, HPMCAS-MF (H-CSUn). This multidrug nanosystem was
evaluated based on its physicochemical properties, in vitro and ex vivo intestinal
permeability, and in vivo performance.
5.3.1 pH-responsive behavior of the multistage polymer–PSi nanocomposite
Firstly, the surface morphology of the H-CSUn NPs and polymeric NPs without PSi were
evaluated using HR-SEM (Figure 15A). The polymeric NPs displayed spherical shape with
smooth surface, whereas the H-CSUn NPs showed an uneven surface indicating a successful
encapsulation of CSUn NPs in the polymeric matrix. The successful coating was further
confirmed by evaluating the pH-responsivity of the system using TEM, size of the
nanocarriers, and the drug release profiles. From the TEM images (Figure 15B), it can be
clearly observed that the NPs remained intact in acidic pH until 1 h, whereas in pH 6.0 and
6.8,the polymeric coat started to dissolve in the first 10 min and completely dissolved after
1 h, releasing the encapsulated CSUn NPs. Furthermore, the pH responsiveness of the
nanosystem was confirmed with the decrease in the size of the NPs from 830 to 203 nm
when the pH was changed from 1.2 to 6.8 (Figure 15C). The pH responsivity of the
nanosystem can be attributed to pH dependent solubility of HPMCAS-MF, which only
dissolved at pH ? 6 [279].
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Figure 15 (a) HR-SEM images of the morphology of HPMCAS-MF polymeric NPs and HPMCAS-
MF coated CSUn NPs (scale bar = 500 nm). (b) TEM images showing the pH-
responsive dissolution behavior of the H-CSUn NPs after incubation at different buffer
solutions of pH values (1.2, 4, 6 and 6.8) for 10 min and 1 h. Dissolution initiated at
pH ? 6.0, wherein the polymeric coat start to dissolve in the first 10 min and then was
completely dissolved in 1 h. (c) Particle size of the H-CSUn NPs after incubating with
different buffers at pH values of 1.2, 4, 6.0, 6.8 and 7.4. Data is shown as mean ± SD
(n = 3). In vitro cumulative drug release profiles of (d) GLP-1 and (e) DPP4 inhibitor
from H-CSUn at pH 1.2 and FaSSiF (pH 6.8) at 37 °C. Data is shown as mean ± SD
(n = 3). Copyright © (2015) Elsevier B.V., reprinted with permission from publication
(III).
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The in vitro drug release behavior was also studied for these systems in two different
release media: pH 1.2 solution for 2 h and in FaSSiF (pH 6.8) for 6 h, mimicking its passage
in the GI tract. For GLP-1 (Figure 15D), the NPs were able to successfully retain the loaded
GLP-1 at pH 1.2 with no detectable amounts of GLP-1 released in the gastric conditions.
Nonetheless, the same nanosystem showed a burst GLP-1 release (∼37%) in FaSSiF
medium. This pH-dependent release of GLP-1 was due to the dissolution of the enteric coat
at pH>6, as discussed above. Nonetheless, the release of GLP-1 from the NPs was
incomplete, which could be explained by the strong hydrophobic interactions between the
NPs and the peptide, slower degradation rate of UnPSi, and irreversibly adsorbed peptide
on the pore walls [22, 199]. This delayed drug release profile avoids the premature release
and degradation of the peptide in the stomach, and increases the available amount of GLP-
1 for absorption in the intestine. In the case of DPP4 inhibitor release (Figure 15E), a burst
release of DPP4 inhibitor was observed in both gastric and intestinal conditions, which
suggested the presence of the drug on the surface of the NPs [305]. This can be due to the
high aqueous solubility of the inhibitor, nano-size of the particles, and low drug entrapment
[217, 306]. Nevertheless, the DPP4 inhibitor has been shown active after oral
administration, thereby making it therapeutically available despite of the premature release
in the stomach [81, 82].
In summary, the results above demonstrated successful formation of pH sensitive
coatings on CSUn NPs, which enabled site-specific release of GLP-1 only in the intestine.
5.3.2 Cellular viability study
Cytotoxicity of the NPs was evaluated in AGS cells, a gastric epithelial cell line originated
from human gastric adenocarcinoma for 3 h, and in intestinal cell lines, Caco-2 and HT29-
MTX cells, for 12 h. The evaluation of the cellular viability in these three cell lines for
different time points represents the maximum transit times in the GI tract when the
nanocarriers are orally administered. Moreover, the several concentrations tested also avail
information regarding any component or concentration-dependent toxicity. The cellular
toxicity of UnPSi, CSUn and H-CSUn NPs were tested in different concentrations (25–400
?g/mL).
The cellular toxicity results for all the NPs are shown in Figure 16. The bare UnPSi NPs
showed a concentration-dependent toxicity in the intestinal cell lines; however, the cell
viability remained higher than 80% in the gastric cells. Moreover, the CSUn NPs showed
improved cytocompatibility with cell viability values above 80% for all the three cell lines
tested. The enhanced cytocompatibility can be attributed to the chitosan, which has been
previously reported to be biocompatible and non-toxic [244, 247]. Comparing the cell lines,
higher cytotoxicity was observed in Caco-2 cells as compared to the HT29-MTX cells,
which can be explained by the presence of a mucus layer on HT29-MTX cells, thus avoiding
close interactions of the NPs with the cell surfaces [292]. The final multistage H-CSUn NPs
also showed high cellular viability for all the tested concentrations and cells, thus
demonstrating the fact that the polymeric coating did not have any harmful effect on
cytocompatibility. In addition, HPMCAS-MF, the pH responsive polymer used in this
study, has already been approved by the FDA [277].
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Figure 16 Cell viability of the GI cells exposed to PSi NPs (modified and unmodified with
chitosan) assessed by the CellTiter-Glo® luminescence assay. The ATP contents of AGS
(3 h), Caco-2 (12 h) and HT29-MTX (12 h) cells after the incubation with different PSi
NPs at different concentrations was investigated. The NPs were incubated with the cells
at 37 °C. Statistical analyses were made by one-way analysis of variance (ANOVA)
with Bonferroni post-test. All the data sets were compared to the negative control
HBSS–HEPES buffer. The levels of significance were set at probabilities of *p < 0.05,
**p < 0.01, and ***p < 0.001). Data is shown as mean ± SD (n = 3). Copyright ©
(2015) Elsevier B.V., reprinted with permission from publication (III).
5.3.3 Enhanced intestinal permeability of GLP-1 across cell monolayers
The efficiency of the multistage nanosystems to enhance the intestinal permeability of GLP-
1 and DPP4 inhibitor was evaluated using a triple co-culture model based on Caco-2, HT29-
MTX and Raji B cells, as described in Section 4.5.5. The permeability profiles and apparent
permeability (Papp) coefficients for the GLP-1 and DPP4 inhibitor are shown in Figure
17A–D. The GLP-1 permeability profiles (Figure 17A) showed significantly enhanced
GLP-1 transport when encapsulated into the H-CSUn NPs, which was also shown by a
significant increase in the Papp (p < 0.01) (Figure 17B). The enhanced GLP-1 permeability
can be explained by the presence of mucoadhesive and permeation enhancing chitosan on
the surface of the NPs that augmented the passage of peptides to the basolateral side [28,
307, 308]. When the DPP4 inhibitor was included in the nanosystem (designated as H-CSUn
(D)), the GLP-1 permeation was further enhanced with significant increase in the Papp value
(p < 0.001). This increase of the GLP-1 transport across the cell monolayers can be
attributed to the presence of DPP4 inhibitor in the system. DPP4 inhibitor is responsible for
the inhibition of the DPP4 enzyme that is accountable for rapid degradation of GLP-1,
leading to a very short half-life of GLP-1 of ~2 min [59, 72, 309]. This short half-life of
GLP-1 is one of the major limiting factors for its use in T2DM therapy, due to which a
continuous administration of GLP-1 is required. Therefore, addition of DPP4 inhibitor in
the nanosystem greatly increases the amount of active GLP-1 permeation across the
intestinal monolayer. In addition, DPP4 inhibitor has also been reported to have beneficial
effects on the treatment of T2DM in humans, preventing weight gain, potentiation of ?–cell
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function, and suppression of plasma glucagon [72]. The permeability of DPP4 inhibitor
across the intestinal cell monolayers was also studied (Figure 17C). There were no
significant changes observed in the permeability profiles or Papp (Figure 17D) for both the
pure drug solution and H-CSUn (D).
Figure 17  In vitro permeability profiles of (a) GLP-1 and (b) its apparent permeability (Papp)
coefficient. In vitro permeability profiles of (c) DPP4 inhibitor and (d) its Papp
coefficient. Permeability was evaluated across the Caco-2/HT-29/Raji B triple co-
culture monolayers. The experiments were performed from the apical-to-basolateral
chamber in HBSS–HEPES buffer (pH 7.4) at 37 °C. Data is shown as mean ± SD (n =
3). One-way ANOVA was performed with the level of significance set at a probability
of ***p < 0.001. (e) DPP4 enzyme activity studied in the Caco-2/HT29-MTX/Raji B
triple co-culture monolayers in the presence of DPP4 inhibitor solution (pure drug)
and from the H-CSUn NPs (H-CSUn (D)). One-way ANOVA was performed with the
level of significance set at a probability of ***p < 0.001. Copyright © (2015) Elsevier
B.V., reprinted with permission from publication (III).
Furthermore, to demonstrate the involvement of DPP4 inhibitor in the enhancement of
the GLP-1 permeability, the activity of the DPP4 enzyme in the cell monolayers with and
without the inhibitors was evaluated. The enzyme activities of the cell monolayers incubated
with buffer, pure inhibitor solution or H-CSUn (D) are shown in Figure 17E. The results
showed significant reduction in the enzyme activity when treated with the DPP4 inhibitor,
either as a solution (p < 0.001) or as NPs (p < 0.001). Thus, it can be concluded that the
DPP4 inhibitor is a critical component of the nanosystem to promote the absorption of GLP-
1 across the intestinal epithelium in an intact form. Additionally, the enzyme activity study
also showed that the activity of DPP4 inhibitor was preserved throughout the coating
process in the AFR experiments.
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5.3.4 Ex vivo GLP-1 and DPP4 inhibitor permeability
The permeability of GLP-1 and DPP4 inhibitor from the H-CSUn NPs was further
investigated ex vivo using ligated loops of freshly excised rat intestine tissues [126]. From
the GLP-1 permeability profiles shown in Figure 18A, it can be observed that the NPs
significantly enhanced the intestinal permeability of GLP-1, with 3.9-fold higher amounts
of GLP-1 permeated after 3 h as compared to the control (GLP-1 + DPP4 inhibitor solution)
(p >0.05). The result indicated absorption enhancement of GLP-1, which can be attributed
the presence of chitosan and DPP4 inhibitor in the nanosystem. Furthermore, the
permeability profile of DPP4 inhibitor (Figure 18B) showed that the difference between the
control and the H-CSUn NPs was insignificant. The ex vivo GLP-1 and DPP4 inhibitor
permeability results are in accordance with the results obtained from the in vitro cell
monolayer studies (Section 5.3.3).
Figure 18 Cumulative (A) GLP-1 and (B) DPP4 inhibitor transported across the rat intestine
tissues in an ex vivo ligated intestinal loop at 37 °C in oxygenated Krebs Ringer buffer.
The level of significance were set at a probability of *p < 0.05. Data shown as mean ±
SEM (n = 3). (C) Confocal microscopy images of the intestinal mucoadhesion study
with H-CSUn NPs (scale bar = 100 μm). The NPs were incubated with the ligated
intestinal loop at 37 °C for 3 h. The tissues were embedded in paraffin and cut in 5 μm
sections. The tissues’ sections were then dewaxed, rehydrated and stained. Red: WGA
AlexaFluor 594; green: AF488-conjugated NPs; blue: DAPI; and yellow: co-
localization of mucus and NPs (IV).
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In addition to the permeability study, the ability of the NPs to interact with the rat
intestinal epithelium was also evaluated using confocal microscopy, as shown in Figure
18C. The NPs demonstrated good interactions with the surface of the intestinal epithelia
after 3 h incubation. The observed intestinal adhesion can once again be attributed to the
presence of the mucoadhesive chitosan in the NPs [249]. Similar results were also observed
with H-CSUn NPs interacting with the intestinal cell lines (III). Overall, from the ex vivo
studies it could be established that the H-CSUn NPs efficiently enhanced the GLP-1
permeability across the intestinal epithelia.
5.3.5 In vivo effect of the nanocarrier
After demonstrating the cytocompatibility, enhanced interaction with the intestinal
epithelium and augmented intestinal permeability of GLP-1, the efficacy of H-CSUn NPs
was further evaluated in vivo in diabetic rats. The NPs were administered to the diabetic rats
by oral gavage, and the blood glucose levels were evaluated, as shown in Figure 19A. After
oral administration, the H-CSUn NPs showed notable anti-hyperglycemic effect as
compared to the control (GLP-1 and DPP4 inhibitor solution) at 30, 60 and 120 min (p <
0.05).
Figure 19 (A) Blood glucose levels in diabetic rats after oral administration of H-CSUn NPs at
the dose of GLP-1 of 250 μg/kg in T2DM rat. Data shown as mean ± SEM (n = 3) (IV).
To further understand the results clearly, a decrease in blood glucose levels, decrease in
blood glucose levels (%) was also calculated using Eq. (2). The decrease in blood glucose
levels (%) of the H-CSUn NPs was calculated to be 45% and 27 % when compared to the
control and the empty NPs, respectively. These values demonstrated that the blood glucose
levels were markedly lowered after oral administration of the H-CSUn NPs as compared to
the controls. The decrease in the blood glucose levels can be attributed to the powerful
insulinotropic peptide, GLP-1, which stimulates the pancreatic insulin secretion and release
in a glucose-dependent manner, and the inhibition of the degradation of GLP-1 by the
presence of the DPP4 inhibitor [59, 65, 68]. Furthermore, the advantageous properties of
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the multistage nanosystem to protect the GLP-1 in the harsh gastric conditions with burst
release only in the intestine, enhanced interaction with the intestinal membrane and
augmented GLP-1 permeability had a combined beneficial effect to deliver the GLP-1 and
DPP4 inhibitor simultaneously. In summary, the H-CSUn NPs exhibited potential as a
nanocarrier system for oral delivery of GLP-1 and DPP4 inhibitor, simultaneously.
5.4 Influence of L-cysteine and CPP functionalization of chitosan-
modified PSi nanoparticles on intestinal permeability of insulin (V)
The ability of chitosan modified PSi based micro- and nanoparticles to enhance the intestinal
permeability of proteins and peptides has already been established. Thus, this part of the
dissertation aimed at potentiating the permeation enhancing effect of chitosan-modified NPs
by further surface modifications. For this, L-cysteine (CYS-CSUn) or CPP (CPP-CSUn)
were supplemented to the surface of CSUn NPs. These nanocarriers were characterized
based on the different physicochemical properties, insulin loading and in vitro insulin
release behavior. The effect of these surface modifications on the insulin intestinal
permeability was also evaluated along with the study of insulin uptake and transport
mechanism studies from these nanocarriers across the triple co-culture intestinal cell model.
5.4.1 Insulin permeability across the intestinal epithelium
The successful surface modification of the NPs to form CSUn, CYS-CSUn and CPP-CSUn
was confirmed by the physicochemical characterization, which is explained in detail
elsewhere (V). L-cysteine was used to add a thiol groups to the surface of the CSUn NPs,
as thiolated NPs have been shown to have advantageous influence on the mucoadhesivity
and permeation enhancement [263, 310, 311]. In addition, oligoarginine CPP was selected
for further surface functionalization of the NPs as the positively charged structure has been
shown to enhance the cellular interactions and translocation of the NPs [20, 273].
The ability of these NPs to enhance the intestinal permeability of insulin was evaluated
across the triple co-culture intestinal model, as described above (Section 4.5.5). The
permeability profiles and the enhancement ratio of the Papp coefficients are shown in
Figures 20A and 20B, respectively.
A significant increase in the insulin permeability was observed after modification in the
following order: CYS-CSUn > CPP-CSUn > CSUn. A 17- and 12-fold enhancement in the
Papp coefficient were observed for the CYS-CSUn and CPP-CSUn, respectively, when
compared to CSUn. The presence of thiol groups on the surface of the CYS-CSUn NPs
increased the interactions with the mucin glycoproteins present in the intestinal epithelia,
thereby enhancing the mucoadhesivity of the NPs and the NP–cell interactions [30].
Additionally, the thiol groups have been reported to stimulate the opening of the TJs of the
intestinal cells, thus promoting the insulin permeation across the cell monolayers [265, 267].
In the case of CPP-CSUn, the ability of the CPP to interact with the glycosaminoglycans
present on the cell’s surface and enter into the cells via endocytic pathway could be the
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reason for the observed enhanced permeation [20, 271]. Therefore, it could be concluded
that the permeation enhancing effect of CSUn can be significantly improved by the
modification of CSUn NPs with either L-cysteine or CPP.
Figure 20 (A) In vitro permeability profiles of insulin from different NPs (CSUn, CYS-CSUn, and
CPP-CSUn) across the Caco-2/HT-29/Raji B triple co-culture cell monolayers. (B) The
enhancement ratios of the Papp coefficients of insulin from the different NPs. The levels
of significance were set at probabilities of ***p < 0.001 for comparison between CSUn
and CYS-CSUn NPs, and between CSUn and CPP-CSUn NPs, and ##p < 0.01 for
comparison between CYS-CSUn and CPP-CSUn NPs. Data shown as mean ± SD (n 
3). Copyright © (2016) John Wiley & Sons, Inc., reprinted with permission from
publication (V).
5.4.2 Cell–nanoparticle interactions
After demonstrating the permeation enhancing effect of the NPs, they were further analyzed
for the interactions with the intestinal cell lines. The interactions were studied qualitatively
using confocal fluorescence microscopy imaging (Figure 21A) and TEM (Figure 21B),
and quantitatively using flow cytometry (Figure 21C). The qualitative studies were
performed with the triple co-culture intestinal cell monolayer (Section 4.5.5). In the confocal
fluorescence microscopy images, it was demonstrated that although the CSUn NPs were
interacting with the mucus layer, much higher interactions were observed for the CYS-
CSUn and CPP-CSUn, which could be seen by the large amounts of co-localized NPs with
the mucus. Similar observations were also made with TEM images, where the CYS-CSUn
and CPP-CSUn showed higher interactions compared to the CSUn NPs. These qualitative
results were further confirmed by quantitative flow cytometry analyses, as shown in Figure
21C. The flow cytometry results indicated that the percentage of positive events was
significantly higher for CYS-CSUn and CPP-CSUn NPs as compared to CSUn, which
corroborated the qualitative studies.
For CYS-CSUn NPs, the thiol groups immobilized on the surface forms disulfide bonds
with the mucin glycoproteins, thus, leading to mucoadhesion [265, 267]. In the case of CPP-
CSUn NPs, the enhanced interactions with the mucus layer of the intestinal cells can be
attributed to the presence of positively charged oligoarginine CPP on the surface of the NPs
56
[20, 271]. The results obtained from this study are in accordance with the insulin intestinal
permeability study (Section 5.4.1), where the CYS-CSUn and CPP-CSUn showed further
augmentation of insulin permeation as compared to the CSUn NPs.
Figure 21 In vitro NP– cell interaction study after incubating the NPs with the cells at 37 °C for
3 h. (A) 3D confocal fluorescence microscope images of the cell monolayers interacting
with different NPs (Red: WGA AlexaFluor 594; Green: AF-488 NPs; and Yellow: Co-
localization of mucus and NPs). (B) TEM images of flat embedded ultrathin sections of
cell monolayers interacting with different NPs. (C) Flow cytometry quantitative
analysis of the Caco-2/HT29-MTX co-culture cells interacting with different NPs. The
levels of significance were set at the probability of **p < 0.01 between the CSUn and
CYS-CSUn NPs or CPP-CSUn NPs. Copyright © (2016) John Wiley & Sons, Inc.
reprinted with permission from publication (V).
5.4.3 Insulin transport and cellular uptake mechanisms
The insulin permeation and cellular interaction studies showed significant augmentation of
the intestinal insulin permeability after the L-cysteine and CPP modifications of the CSUn
NPs. However, the transport and uptake mechanisms involved for such NPs have not been
well studied before. Therefore, in this study, the possible uptake and transport mechanisms
of insulin-loaded NPs across the triple co-culture cell monolayers were investigated in
detail.
There are several possible drug intestinal uptake/transport mechanisms at the intestinal
level, such as paracellular, active transport, adsorptive endocytosis, and electrostatic
interactions (Figure 5). To examine the possible involvement of these mechanisms, insulin-
loaded NPs were incubated with the cell monolayers in the presence of different uptake
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inhibitors, followed by insulin association and transport studies across the cell monolayers.
The insulin associated with the monolayers is shown as the amount of insulin per mg of the
total protein content of the cell monolayers and plotted as the percentage with respect to the
control without any inhibitors (Figure 22A). The insulin transported in the presence of
inhibitors is shown in Figure 22B as a percentage of the control.
Figure 22 (A) Uptake and (B) transport of insulin from the different NPs across the triple co-
culture cell monolayers in different conditions. All the data sets were compared to the
respective controls. The levels of significance were set at probabilities of *p < 0.05,
**p < 0.01, and ***p < 0.001. Data are shown as mean ± SD (n = 3). Copyright ©
(2016) John Wiley & Sons, Inc., reprinted with permission from publication (V).
The involvement of active transport was disclosed, as a significant decrease in insulin
uptake and transport were seen in the presence of sodium azide and at 4 °C, which have
been shown to inhibit the active transport in the cells [119]. Likewise, pre-treatment with
sodium chlorate exhibited the most significant reduction in the uptake and transport of
insulin for all the tested NPs. Sodium chlorate has been shown to inhibit the electrostatic
interactions between the NPs and the glycocalyx of the cells, inhibiting the
glycosaminoglycan sulfation [119, 312]. Moreover, the electrostatic interactions between
the NPs and the integrin on the cell surfaces have been reported to be the primary step to
stimulate the cascade of reactions for opening the TJs [253]. Additionally, the inhibition
with protamine and chlorpromazine also reduced the insulin uptake and transport across the
cell membrane significantly, suggesting the involvement of adsorptive endocytosis and
clathrin-mediated endocytosis. Protamine is responsible for the inhibition of adsorptive
endocytosis, and chlorpromazine has been stated to disrupt the assembly and disassembly
of clathrin, thus hindering the receptor recycling involved in the clathrin-mediated
endocytosis [313, 314]. However, the presence of fillipin inhibitor did not show any
significant changes in the transport and uptake of insulin, suggesting the absence in the
involvement of caveolae-mediated endocytosis. Fillipin inhibits the caveolae-mediated
endocytosis by precipitating cholesterol that damages the caveolae structure [315].
Overall, from this study it was observed that there is probable involvement of several
pathways, such as active transport, electrostatic interactions, adsorptive and the clathrin-
mediated endocytosis process, in the uptake and transport of insulin from these modified
and insulin-loaded PSi-based NPs.
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6 Conclusions
In this dissertation, PSi-based micro and nanoparticulate systems were developed as oral
carrier systems for insulin and GLP-1, and were evaluated based on their ability to enhance
the intestinal permeability of the encapsulated drugs.
In the first study, the influence of different surface chemistries and chitosan surface
modification methods of PSi microparticles on insulin permeability across intestinal cell
monolayers were evaluated. Comparing different surface chemistries, AnnTHCPSi
microparticles showed significantly higher insulin permeability and uptake as compared to
AnnUnTHCPSi microparticles. The highest insulin permeation and uptake was observed
for chitosan-conjugated AnnUnTHCPSi microparticles, which was elucidated by high
interactions with the intestinal cells, as clearly shown in the confocal and TEM images.
In the next study, three different nanosystems fabricated from three different
biomaterials, polymer, lipid and PSi, were evaluated as potential oral GLP-1 delivery
systems. Chitosan coating of the NPs greatly improved these nanosystems by sustaining the
release of GLP-1, enhancing the cellular compatibility and interactions, and augmenting the
GLP-1 transport across the intestinal cellular monolayers. However, among the three
nanosystems, chitosan-coated PSi NPs showed the best performance with the highest GLP-
1 loading, sustained GLP-1 release behavior and the highest amount of GLP-1 permeated,
thus demonstrating itself as a potential carrier for oral GLP-1 delivery.
Next, taking advantage of the potential of PSi NPs and the chitosan surface conjugation
to overcome the physical intestinal barriers, an advanced multistage pH-responsive
polymer/PSi nanocomposite was developed using AFR technology for dual-drug delivery
of GLP-1 and DPP4 inhibitor. In addition to the mucosal and intestinal barriers, this
nanosystem was also aimed at overcoming the biochemical barriers in the GI tract by
protecting the encapsulated GLP-1 from the harsh gastric conditions and prolonging the
GPL-1 half-life by simultaneous delivery of DPP4 inhibitor from the same nanosystem. This
dual-drug delivery system exhibited enhanced GLP-1 permeability across both in vitro
intestinal cell monolayers and ex vivo rat intestinal tissues. This augmented permeability
could be attributed to high interactions with the intestinal epithelium and inhibition of the
DPP4 enzymes present in the intestinal epithelium. Moreover, when orally administered in
diabetic rats, the GLP-1 and DPP4 inhibitor loaded NPs showed a hypoglycemic effect as
compared to the drug solution and empty NPs. Thus, this co-therapeutic multifunctional
nanosystem exhibited high clinical potential as an oral nanocarrier for GLP-1 in
combination with DPP4 inhibitor.
Finally, mucoadhesive and permeation enhancement of CSUn NPs were further
enhanced by modifying the NPs’ surface either by thiolation or by addition of CPP. As
compared to CSUn NPs, L-cysteine and CPP modifications showed 17-fold and 12-fold
enhancement in the insulin permeability across the intestinal cell monolayers, respectively.
Furthermore, the involvement of several pathways in the uptake and transport of insulin
across intestinal cell monolayers from different NPs were also observed. Electrostatic
interactions between the NPs and the cell membrane were the most dominant mechanism,
with the involvement of active transport as well. In addition, adsorptive endocytosis and
clathrin-mediated endocytosis were also shown to be involved to some extent in the insulin
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uptake and transport mechanisms. Overall, it was shown that further modifications of the
CSUn NPs with either thiolation or CPP could significantly enhance the interactions with
the intestinal cells and the intestinal permeability of insulin, thus displaying potential for
improving oral insulin delivery systems.
In conclusion, in this dissertation, PSi, polymer and lipid-based systems with surface
modifications using different mucoadhesive and permeation enhancing excipients and
enteric coatings were developed. The potential of these nanosystems for oral insulin/GLP-
1 delivery were assessed. Overall, the PSi-based platforms showed great potential for oral
delivery of proteins and peptides for the DM therapy.
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